

Prior Authorization Criteria Last

Updated: March 19, 2025

Effective Date: April 1, 2025



DualChoice

2025 Prior Authorizations

(List of Prior Authorizations)

PLEASE READ CAREFULLY: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE PRIOR AUTHORIZATIONS ON DRUGS THAT WE COVER IN THIS PLAN.

Note to existing members: Beneficiaries must use network pharmacies to access their prescription drug benefit. “Benefits, List of Covered Drugs, pharmacy and provider networks and copayments may change from time to time throughout the year and on January 1 of each year.”

IEHP DualChoice (HMO D-SNP) is an HMO Plan with a Medicare contract. Enrollment in IEHP DualChoice (HMO D-SNP) depends on contract renewal.

You can get this document for free in other formats, such as large print, braille, and/or audio. Call IEHP DualChoice Member Services at 1-877-273-IEHP (4347), 8am-8pm (PST), 7 days a week, including holidays. TTY users should call 1-800-718-4347. The call is free.

Puede obtener este documento gratis en otros formatos, como letra grande, Braille y/o audio. Llame a Servicios para Miembros de IEHP DualChoice al 1-877-273-IEHP (4347), 8am a 8pm (Hora del Pacífico), los 7 días de la semana, incluidos los días festivos. Los usuarios de TTY deben llamar al 1-800-718-4347. La llamada es gratuita.

您可以免費索取本文件的其他格式，例如大字版、盲文版和/或音訊版。請致電1-877-273-IEHP (4347) 與IEHP DualChoice會員服務處聯絡。服務時間為上午8點至晚上8點（太平洋標準時間），每週7天，包括節假日。TTY使用者應撥打1-800-718-4347。電話服務免費。

Quý vị có thể tải miễn phí tài liệu này ở các định dạng khác, chẳng hạn như bản in cỡ lớn, chữ nổi Braille và/hoặc tệp âm thanh. Hãy gọi Ban Dịch Vụ Hội Viên IEHP DualChoice theo số 1-877-273-IEHP (4347), 8 giờ sáng - 8 giờ tối (Múi giờ PST), 7 ngày trong tuần, kể cả các ngày lễ. Người dùng TTY vui lòng gọi số 1-800-718-4347. Miễn phí cước gọi.

ABELCET

Products Affected

- ABELCET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: conventional Amphotericin B. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ABILIFY MAINTENA

Products Affected

- ABILIFY ASIMTUFI
INTRAMUSCULAR
SUSPENSION,EXTENDED REL
SYRING 720 MG/2.4 ML, 960 MG/3.2
ML
 - ABILIFY MAINTENA
INTRAMUSCULAR
- SUSPENSION,EXTENDED REL
RECON 300 MG, 400 MG
 - ABILIFY MAINTENA
INTRAMUSCULAR
SUSPENSION,EXTENDED REL
SYRING

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documented history of receiving oral aripiprazole without any clinically significant side effects. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: Invega Sustenna, Invega Trinza or Risperdal Consta. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ACITRETIN

Products Affected

- *acitretin*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: calcipotriene, clobetasol, cyclosporine, fluocinonide, methotrexate, or Tazorac. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ACTIMMUNE

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Endocrinologist, Hematologist, Infectious Disease specialist, Immunologist, Oncologist, Orthopedist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ADEFOVIR

Products Affected

- *adefovir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Gastroenterologist, Hepatologist, Infectious Disease specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ADHD

Products Affected

- *dexmethylphenidate oral tablet*
- *methylphenidate hcl oral capsule, er biphasic 30-70*
- *methylphenidate hcl oral capsule, er biphasic 50-50*
- *methylphenidate hcl oral solution*
- *methylphenidate hcl oral tablet*
- *methylphenidate hcl oral tablet extended release*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AIMOVIG

Products Affected

- AIMOVIG AUTOINJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist, Headache Specialist, Pain Specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to one of the formulary alternatives: divalproex, valproic acid, or topiramate and failure or clinically significant adverse effects to one of the formulary alternatives: metoprolol, timolol, propranolol. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ALOSETRON

Products Affected

- *alosetron*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Irritable bowel syndrome with diarrhea: Failure or clinically significant adverse effects to the formulary alternative: loperamide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AMBISOME

Products Affected

- AMBISOME
- *amphotericin b liposome*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: conventional Amphotericin B. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AMITRIPTYLINE

Products Affected

- *amitriptyline*
- *amitriptyline-chlordiazepoxide oral tablet*
12.5-5 mg, 25-10 mg
- *perphenazine-amitriptyline*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AMOXAPINE

Products Affected

- *amoxapine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AMPHOTERICIN B

Products Affected

- *amphotericin b*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ANTICONVULSANTS 1

Products Affected

- APTIOM ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG
- EPIDIOLEX
- FYCOMPA ORAL SUSPENSION
- FYCOMPA ORAL TABLET

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to one of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ANTICONVULSANTS 2

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- DIACOMIT
- FINTEPLA
- MOTPOLY XR ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Clobazam, Fenfluramine, or Stiripentol: Must be used as adjunctive treatment of seizure. Lacosamide: For partial seizure: Failure or clinically significant adverse effects to two of the following: carbamazepine, divalproex, felbamate, gabapentin, levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide. For tonic-clonic seizure: Failure or clinically significant adverse effects to two of the following: lamotrigine, levetiracetam, phenytoin, or topiramate. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ANTINEOPLASTIC

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG
- AKEEGA
- ALECENSA
- ALUNBRIG
- AUGTYRO ORAL CAPSULE 160 MG, 40 MG
- AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG
- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG
- BESREMI
- BOSULIF
- BRAFTOVI
- BRUKINSA
- CABOMETYX
- CALQUENCE (ACALABRUTINIB MAL)
- CAPRELSA
- COMETRIQ
- COPIKTRA
- COTELLIC
- DANZITEN
- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*
- DAURISMO ORAL TABLET 100 MG, 25 MG
- ERIVEDGE
- ERLEADA ORAL TABLET 240 MG, 60 MG
- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*
- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 3 mg, 5 mg*
- FOTIVDA
- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG
- GAVRETO
- *gefitinib*
- GILOTRIF
- GLEOSTINE
- IBRANCE
- ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG
- IDHIFA
- *imatinib oral tablet 100 mg, 400 mg*
- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- IMKELDI
- INLYTA ORAL TABLET 1 MG, 5 MG
- INQOVI
- INREBIC
- IRESSA
- ITOVEBI ORAL TABLET 3 MG, 9 MG
- IWILFIN
- JAKAFI
- JAYPIRCA ORAL TABLET 100 MG, 50 MG
- KISQALI FEMARA CO-PACK
- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)
- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KRAZATI
- *lapatinib*
- LAZCLUZE ORAL TABLET 240 MG, 80 MG
- *lenalidomide*
- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY (10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X 2), 20 MG/DAY (10 MG X 2), 24 MG/DAY (10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)
- LONSURF
- LORBRENA ORAL TABLET 100 MG, 25 MG

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG
- LYNPARZA
- LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)
- MATULANE
- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG
- OJEMDA ORAL SUSPENSION FOR RECONSTITUTION
- OJEMDA ORAL TABLET
- OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG
- ONUREG
- ORGOVYX
- ORSERDU ORAL TABLET 345 MG, 86 MG
- PANRETIN
- *pazopanib*
- PEMAZYRE
- PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)
- POMALYST
- PURIXAN
- QINLOCK
- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG
- REVLIMID
- REVUFORJ ORAL TABLET 110 MG, 160 MG
- REZLIDHIA
- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET
- RUBRACA
- RYDAPT
- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG
- *sorafenib*
- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG
- STIVARGA
- *sunitinib malate*
- SUTENT
- TABLOID
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID
- TIBSOVO
- *torpenz*
- TRUQAP
- TUKYSA ORAL TABLET 150 MG, 50 MG
- TURALIO ORAL CAPSULE 125 MG, 200 MG
- VANFLYTA
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION
- VIZIMPRO
- VONJO
- VORANIGO ORAL TABLET 10 MG, 40 MG
- VOTRIENT
- WELIREG
- XALKORI ORAL CAPSULE

- XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG
- XERMELO
- XOSPATA
- XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK),
- 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)
- XTANDI
- YONSA
- ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

APREPITANT

Products Affected

- *aprepitant*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months. |
| Other Criteria | Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to one of the formulary 5-HT3 antagonist alternatives: ondansetron or granisetron except when the member is on any chemotherapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ARCALYST

Products Affected

- ARCALYST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrently taking any tumor necrosis factor (TNF)-blocking agents such as Enbrel, Humira, or Remicade. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ARIKAYCE

Products Affected

- ARIKAYCE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation: positive sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist, Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ARIPIPIRAZOLE

Products Affected

- OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of difficulty or inability to swallow or failure or clinically significant adverse effects to the formulary alternative: oral aripiprazole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ARMODAFINIL

Products Affected

- *armodafinil*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Narcolepsy: Failure or clinically significant adverse effects to all of the formulary alternatives: dextroamphetamine and methylphenidate. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ATOVAQUONE

Products Affected

- *atovaquone*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Pneumocystic pneumonia: Failure or clinically significant adverse effects to the formulary alternative: trimethoprim/sulfamethoxazole. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AUBAGIO

Products Affected

- AUBAGIO
- *teriflunomide*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AUSTEDO

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with an MAOI. Untreated or inadequately-treated depression, or current suicidality in patients with Huntington disease. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist, Psychiatrist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Chorea (Huntington's Disease): Failure or clinically significant adverse effects to the formulary alternative: tetrabenazine. Reauthorization only: Documentation of positive response to medication therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

AUVELITY

Products Affected

- AUVELITY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

BRONCHITOL

Products Affected

- BRONCHITOL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | New: Documentation that patient has passed the BRONCHITOL Tolerance Test (BTT). Reauthorization only: Documentation of positive response to medication therapy (improvement in lung function as determined by change in FEV1). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CASPOFUNGIN

Products Affected

- *casposfungin*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CIMZIA

Products Affected

- CIMZIA POWDER FOR RECONST
- CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Rheumatologist, Dermatologist, or Gastroenterologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Rheumatoid Arthritis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Rinvoq, or Xeljanz IR/XR. Crohn's Disease: Failure or clinically significant adverse effects to two of the formulary alternatives: Humira, Stelara, or Skyrizi. Psoriatic arthritis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Stelara, Xeljanz IR/XR, Rinvoq, or Skyrizi. Ankylosing spondylitis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Rinvoq, or Xeljanz IR/XR. Non-radiographic Axial Spondyloarthritis: Failure or clinically significant adverse effects to the formulary alternative: Cosentyx. Plaque psoriasis: Failure or clinically significant adverse effects to two of the formulary alternatives: Humira, Stelara, Enbrel, or Skyrizi. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CLOMIPRAMINE

Products Affected

- *clomipramine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Any of the following: Concomitant use of an MAOI, or Use within 14 days of discontinuing an MAOI, or Concomitant use of linezolid, or Concomitant use of intravenous methylene blue, or Use during the acute recovery period after a myocardial infarction. |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Obsessive-Compulsive Disorder: Failure or clinically significant adverse effects to two of the formulary alternatives: fluoxetine, fluvoxamine, or sertraline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CONSTIPATION AGENTS

Products Affected

- MOVANTIK

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to one of the formulary alternatives: lactulose or polyethylene glycol. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CORLANOR

Products Affected

- CORLANOR ORAL SOLUTION • *ivabradine*
- CORLANOR ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Heart failure in adult patients: Documented New York Association (NYHA) class II to IV heart failure with an ejection fraction of less than or equal to 35% and sinus rhythm with a resting heart rate greater than or equal to 70 beats per minute (bpm). Documentation that patient is on maximally tolerated dose of beta blocker or has a history of a documented intolerance, contraindication or a hypersensitivity to beta blocker. Documented concurrent use with an ACE inhibitor or ARB, unless both are not tolerated or contraindicated. Heart failure in pediatric patients: Documented NYHA/Ross class II to IV heart failure with an ejection fraction of less than or equal to 45% and sinus rhythm with a resting heart rate greater than or equal to 105 bpm in the age subset 6-12 months, greater than or equal to 95 bpm in the age subset 1-3 years, greater than or equal to 75 bpm in the age subset 3-5 years, greater than or equal to 70 bpm in the age subset 5-18 years</p> |
| Age Restrictions | |
| Prescriber Restrictions | Cardiologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

COSENTYX

Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals. |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Ankylosing spondylitis: For adults, failure or clinically significant adverse effects to both of the formulary alternatives: Enbrel and Humira. Psoriatic arthritis: For adults, failure or clinically significant adverse effects to both of the formulary alternatives: Enbrel and Humira. Plaque Psoriasis: For adults, failure or clinically significant adverse effects to one of the formulary alternatives: Humira, Enbrel, or Skyrizi. Non-radiographic Axial Spondyloarthritis: Failure or clinically significant adverse effects to a non-steroidal anti-inflammatory drug (NSAID) or has an intolerance or contraindication to NSAID. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

CYCLOBENZAPRINE

Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Documentation explaining specific benefit established with the medication, and how that benefit outweighs the potential risk |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DALFAMPRIDINE

Products Affected

- *dalfampridine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Moderate or severe renal impairment (CrCL 50 mL/min or less). |
| Required Medical Information | Concurrently on a disease-modifying agent for multiple sclerosis. Documentation of difficulty walking (such as timed 25-foot walk test: Patient must be able to walk 25 feet within 8-45 sec). Reauthorization only: Documentation of positive response to medication therapy. |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DALIRESP

Products Affected

- DALIRESP
- *roflumilast*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Liver impairment, moderate to severe (Child-Pugh B or C). |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: either Wixela or Fluticasone/Salmeterol, Anoro Ellipta, Serevent, Spiriva or Tudorza. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DEFERASIROX

Products Affected

- *deferasirox oral tablet, dispersible*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hematologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DESIPRAMINE

Products Affected

- *desipramine*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DIAZEPAM SOLUTION

Products Affected

- *diazepam intensol*
- *diazepam oral solution 5 mg/5 ml (1 mg/ml)*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of difficulty or inability to swallow. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DISOPYRAMIDE

Products Affected

- *disopyramide phosphate oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Arrhythmia: Failure or clinically significant adverse effects to two of the formulary alternatives: acebutolol, flecainide, mexiletine, propafenone, quinidine, or sotalol. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DOXEPIN

Products Affected

- *doxepin oral capsule*
- *doxepin oral concentrate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | For the average daily dose of doxepin that is greater than 6 mg: Anxiety: Failure or clinically significant adverse effects to two of the formulary alternatives: buspirone, duloxetine, escitalopram, or venlafaxine. Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DRIZALMA

Products Affected

- DRIZALMA SPRINKLE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of difficulty or inability to swallow an intact capsule or failure or clinically significant adverse effects to the formulary alternative: duloxetine. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DRONABINOL

Products Affected

- *dronabinol*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Chemotherapy-induced nausea and vomiting: Failure or clinically significant adverse effects to two of the formulary alternatives: chlorpromazine, granisetron, metoclopramide, ondansetron, or prochlorperazine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DROXIDOPA

Products Affected

- *droxidopa*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

DUPIXENT

Products Affected

- DUPIXENT PEN
- DUPIXENT SYRINGE
SUBCUTANEOUS SYRINGE 200
MG/1.14 ML, 300 MG/2 ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Initial: eosinophilic asthma: blood eosinophil level greater than or equal to 150 cells/mcl within the past 12 months. Eosinophilic Esophagitis: diagnosis confirmed by esophagogastroduodenoscopy with biopsy. |
| Age Restrictions | |
| Prescriber Restrictions | Initial: Atopic Dermatitis, Prurigo Nodularis: prescribed by or in consultation with a Dermatologist, Allergist or Immunologist. Asthma: prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine. Chronic Rhinosinusitis with Nasal Polyposis: prescribed by or in consultation with an Otolaryngologist, Allergist or Immunologist. Eosinophilic Esophagitis: prescribed by or in consultation with a Gastroenterologist, Allergist, or Immunologist. |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Initial: Atopic Dermatitis: 1) Atopic Dermatitis covering at least 10 percent of body surface area or Atopic Dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas, 2) intractable pruritus or cracking/oozing/bleeding of affected skin, 3) trial of or contraindication to one topical (corticosteroid or calcineurin inhibitor), and 4) no concurrent use with other systemic biologic/JAK inhibitor for Atopic Dermatitis. Asthma: 1) concurrent therapy with a medium, high-dose or maximally-tolerated dose of an inhaled corticosteroid (ICS) and one other maintenance medication, 2) one asthma exacerbation requiring systemic corticosteroid burst lasting 3 or more days within the past 12 months, or one serious exacerbation requiring hospitalization or ER visit within the past 12 months, or poor symptom control despite current therapy as evidenced by at least three of the following within the past 4 weeks: daytime asthma symptoms more than twice/week, any night waking due to asthma, Short-Acting Beta Agonist (SABA) reliever for symptoms more than twice/week, any activity limitation due to asthma, and 3) no concurrent use with Xolair or other Anti-IL5 biologics when used for |

| PA Criteria | Criteria Details |
|----------------------------|---|
| | <p>asthma. Chronic Rhinosinusitis with Nasal Polyposis: 1) evidence of nasal polyps by direct examination, endoscopy or sinus CT scan, 2) inadequately controlled disease as determined by use of systemic steroids in the past 2 years or endoscopic sinus surgery, and 3) trial of one topical nasal corticosteroid. Prurigo Nodularis: 1) chronic pruritis (itch more than 6 weeks), multiple pruriginous lesions, and history or sign of a prolonged scratching behavior, 2) trial of or contraindication to one topical (corticosteroid or calcipotriene). Renewal: Atopic Dermatitis: 1) improvement while on therapy, and 2) no concurrent use with other systemic biologic/JAK inhibitor for Atopic Dermatitis. Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis: improvement while on therapy. Asthma: 1) no concurrent use with Xolair, or other Anti-IL5 biologics for asthma, 2) continued use of ICS and one other maintenance medication, and 3) clinical response as evidenced by: (a) reduction in asthma exacerbations from baseline, (b) decreased utilization of rescue medications, (c) increase in percent predicted FEV1 from pretreatment baseline, or (d) reduction in severity or frequency of asthma-related symptoms. Prurigo Nodularis: improvement or reduction of pruritis or pruriginous lesions.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ELIGARD

Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Oncologist, Urologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

EMSAM

Products Affected

- EMSAM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other serotonergic drugs (i.e. SSRIs, SNRIs, TCAs) |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to all of the formulary alternatives: phenelzine and tranylcypromine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals. |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the following: acitretin, cyclosporine, methotrexate or phototherapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ENDARI

Products Affected

- ENDARI
- *glutamine (sickle cell)*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hematologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ESBRIET

Products Affected

- ESBRIET ORAL CAPSULE
- ESBRIET ORAL TABLET 267 MG, 801 MG
- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Initial authorization: Diagnosis of idiopathic pulmonary fibrosis confirmed by the presence of usual interstitial pneumonia on high resolution computed tomography (HRCT) and/or surgical lung biopsy. Documentation of liver function tests, documentation of baseline forced vital capacity (FVC) greater than or equal to 50 percent of the predicted value AND documentation of percent predicted diffusing capacity of the lungs for carbon monoxide (%DLCO) greater than or equal to 30 percent. |
| Age Restrictions | |
| Prescriber Restrictions | Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ESTROGENS

Products Affected

- DUAVEE
- *estradiol oral*
- *estradiol transdermal patch weekly*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol cream or Premarin Cream. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FENTANYL LOZENGE

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Acute, intermittent, or postoperative pain. |
| Required Medical Information | Documentation of opioid tolerance taking around-the-clock opioid therapy consisting of at least 60mg of oral morphine daily, at least 25mg transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8mg oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer for breakthrough pain of cancer. Patients must remain on around-the clock opioids when taking transmucosal immediate release fentanyl. |
| Age Restrictions | |
| Prescriber Restrictions | Pain Specialist, Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FETZIMA

Products Affected

- FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)
- FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FIRAZYR

Products Affected

- *icatibant*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of hereditary angioedema (HAE), must be confirmed by blood testing. |
| Age Restrictions | |
| Prescriber Restrictions | Allergist, Immunologist, Hematologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

FIRMAGON

Products Affected

- FIRMAGON KIT W DILUENT SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Oncologist, Urologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GENOTROPIN

Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | AGHD(initial): diagnosis confirmed as a result of past diagnosis of childhood-onset GHD, or adult-onset GHD with documentation of hormone deficiency due to hypothalamic-pituitary disease from organic or known causes (eg: damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and documentation of one growth-hormone stimulant test (eg: insulin tolerance test, arginine/GHRH,glucagon,arginine) to confirm adult GHD w/corresponding peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or documented deficiency of 3 anterior pituitary hormones (prolactin,ACTH,TSH,FSH/LH) and IFG-1/somatomedinC below age and gender adjusted normal range as provided by physicians lab. AGHD(reauthorization): Documentation of positive experience by the patient. |
| Age Restrictions | |
| Prescriber Restrictions | Endocrinologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GEODON SOLUTION

Products Affected

- *ziprasidone mesylate*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GILENYA

Products Affected

- *fingolimod*
- GILENYA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Class III or IV heart failure, decompensated heart failure requiring hospitalization, myocardial infarction, stroke, transient ischemic attack or unstable angina within the last 6 months. Concomitant use of Class Ia or Class III anti-arrhythmic drugs. Mobitz type II second-degree or third-degree atrioventricular block, or sick-sinus syndrome unless the patient has a functional pacemaker. QT interval at baseline 500 ms or greater. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | For adults: Failure or clinically significant adverse effects to Aubagio and glatiramer. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GLATIRAMER

Products Affected

- *glatiramer*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GLATOPA

Products Affected

- *glatopa*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GLP1

Products Affected

- MOUNJARO
- OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)
- RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG
- TRULICITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or a personal or family history of medullary thyroid carcinoma (MTC), treatment for obesity or weight loss only, and concurrent use with DPP4 inhibitors. |
| Required Medical Information | For a diagnosis of Type 2 Diabetes Mellitus the patient has a trial and failure, contraindication or intolerance to metformin or any metformin combination product. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Reauthorization only: Documentation of positive response to medication therapy (reduction in HbA1C or maintenance of HbA1c level). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GLYBURIDE

Products Affected

- *glyburide*
- *glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg*
- *glyburide micronized*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to formulary alternative: glipizide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

GUANFACINE

Products Affected

- *guanfacine oral tablet*
- *guanfacine oral tablet extended release 24 hr*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Hypertension: Failure or clinically significant adverse effects to two of the formulary alternatives: benazepril, fosinopril, hydrochlorothiazide, irbesartan, lisinopril, losartan, losartan/hydrochlorothiazide, lisinopril/hydrochlorothiazide, quinapril/hydrochlorothiazide, quinapril, ramipril, or valsartan/hydrochlorothiazide. ADHD: Failure or clinically significant adverse effects to two of the formulary alternatives: amphetamine/dextroamphetamine, dexamethylphenidate, dextroamphetamine, or methylphenidate. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

HRM ANTIPSYCHOTICS

Products Affected

- *molindone oral tablet 10 mg, 25 mg, 5 mg* • *thioridazine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

HUMIRA

Products Affected

- HUMIRA PEN
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA(CF)
- HUMIRA(CF) PEN
- HUMIRA(CF) PEN CROHNS-UC-HS
- HUMIRA(CF) PEN PSOR-UV-ADOL HS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Plaque psoriasis: documentation of psoriasis involving 3% of BSA or greater, or affecting crucial body areas such as hands, feet, face or genitals. |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Gastroenterologist, Ophthalmologist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

HUMIRA PEDIATRIC

Products Affected

- HUMIRA(CF) PEDI CROHNS STARTER
- HUMIRA(CF) PEN PEDIATRIC UC

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IMIPRAMINE

Products Affected

- *imipramine hcl*
- *imipramine pamoate*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

IMPAVIDO

Products Affected

- IMPAVIDO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Females of Reproductive Potential: confirm negative pregnancy status. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INCRELEX

Products Affected

- INCRELEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Pediatric patients with malignant neoplasm or history of malignancy. Use for growth promotion in patients with closed epiphyses. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Endocrinologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INDOMETHACIN

Products Affected

- *indomethacin oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: celecoxib, diclofenac, ibuprofen, meloxicam, nabumetone, naproxen, or sulindac. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INGREZZA

Products Affected

- INGREZZA
- INGREZZA INITIATION PK(TARDIV)
- INGREZZA SPRINKLE

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist, Psychiatrist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Chorea (Huntington's Disease): Failure or clinically significant adverse effects to the formulary alternative: tetrabenazine. Reauthorization only: Documentation of positive response to medication therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INSULIN SUPPLIES PAYMENT DETERMINATION

Products Affected

- 1ST TIER UNIFINE PENTP 5MM 31G
- 1ST TIER UNIFINE PNTIP 4MM 32G
- 1ST TIER UNIFINE PNTIP 6MM 31G
- 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT
- 1ST TIER UNIFINE PNTP 29GX1/2"
- 1ST TIER UNIFINE PNTP 31GX3/16
- 1ST TIER UNIFINE PNTP 32GX5/32
- ABOUTTIME PEN NEEDLE 30G X 8MM
- ABOUTTIME PEN NEEDLE 31G X 5MM
- ABOUTTIME PEN NEEDLE 31G X 8MM
- ABOUTTIME PEN NEEDLE 32G X 4MM
- ADVOCATE INS 0.3 ML 30GX5/16"
- ADVOCATE INS 0.3 ML 31GX5/16"
- ADVOCATE INS 0.5 ML 30GX5/16"
- ADVOCATE INS 0.5 ML 31GX5/16"
- ADVOCATE INS 1 ML 31GX5/16"
- ADVOCATE INS SYR 0.3 ML 29GX1/2
- ADVOCATE INS SYR 0.5 ML 29GX1/2
- ADVOCATE INS SYR 1 ML 29GX1/2"
- ADVOCATE INS SYR 1 ML 30GX5/16
- ADVOCATE PEN NDL 12.7MM 29G
- ADVOCATE PEN NEEDLE 32G 4MM
- ADVOCATE PEN NEEDLE 4MM 33G
- ADVOCATE PEN NEEDLES 5MM 31G
- ADVOCATE PEN NEEDLES 8MM 31G
- ALCOHOL 70% SWABS
- ALCOHOL PADS
- ALCOHOL PREP SWABS
- ALCOHOL WIPES
- AQ INSULIN SYR 1 ML 31G 8MM (RX)
- AQINJECT PEN NEEDLE 31G 5MM
- AQINJECT PEN NEEDLE 32G 4MM
- ASSURE ID DUO PRO NDL 31G 5MM
- ASSURE ID DUO-SHIELD 30GX3/16"
- ASSURE ID DUO-SHIELD 30GX5/16"
- ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"
- ASSURE ID PEN NEEDLE 30GX3/16"
- ASSURE ID PEN NEEDLE 30GX5/16"
- ASSURE ID PEN NEEDLE 31GX3/16"
- ASSURE ID PRO PEN NDL 30G 5MM
- ASSURE ID SYR 0.5 ML 29GX1/2" (RX)
- ASSURE ID SYR 0.5 ML 31GX15/64"
- ASSURE ID SYR 1 ML 31GX15/64"
- AUTOSHIELD DUO PEN NDL 30G 5MM
- BD AUTOSHIELD DUO NDL 5MMX30G
- BD ECLIPSE 30GX1/2" SYRINGE
- BD ECLIPSE NEEDLE 30GX1/2" (OTC)
- BD INS SYR 0.3 ML 8MMX31G(1/2)
- BD INS SYR UF 0.3 ML 12.7MMX30G
- BD INS SYRINGE 1/2 ML 6MMX31G (ONLY FOR 500 UNIT/ML INSULIN)
- BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE
- BD INSULIN SYR 1 ML 25GX1"
- BD INSULIN SYR 1 ML 25GX5/8"
- BD INSULIN SYR 1 ML 26GX1/2"
- BD INSULIN SYR 1 ML 27GX12.7MM
- BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE
- BD INSULIN SYR UF 1 ML 8MMX31G
- BD INSULIN SYRINGE SLIP TIP
- BD LUER-LOK SYRINGE 1 ML
- BD NANO 2 GEN PEN NDL 32G 4MM
- BD SAFETGLD INS 0.3 ML 29G 13MM
- BD SAFETGLD INS 0.5 ML 13MMX29G
- BD SAFETYGLD INS 0.3 ML 31G 8MM
- BD SAFETYGLD INS 0.5 ML 30G 8MM
- BD SAFETYGLD INS 1 ML 29G 13MM
- BD SAFETYGLID INS 1 ML 6MMX31G
- BD SAFETYGLIDE SYRINGE 27GX5/8

- BD SAFTYGLD INS 0.3 ML 6MMX31G
- BD SAFTYGLD INS 0.5 ML 29G 13MM
- BD SAFTYGLD INS 0.5 ML 6MMX31G
- BD SINGLE USE SWAB
- BD UF MICRO PEN NEEDLE 6MMX32G
- BD UF MINI PEN NEEDLE 5MMX31G
- BD UF NANO PEN NEEDLE 4MMX32G
- BD UF ORIG PEN NDL 12.7MMX29G
- BD UF SHORT PEN NEEDLE 8MMX31G
- BD VEO INS 0.3 ML 6MMX31G (1/2)
- BD VEO INS SYRING 1 ML 6MMX31G
- BD VEO INS SYRN 0.3 ML 6MMX31G
- BD VEO INS SYRN 0.5 ML 6MMX31G
- BORDERED GAUZE 2"X2"
- CAREFINE PEN NEEDLE 12.7MM 29G
- CAREFINE PEN NEEDLE 4MM 32G
- CAREFINE PEN NEEDLE 5MM 32G
- CAREFINE PEN NEEDLE 6MM 31G
- CAREFINE PEN NEEDLE 8MM 30G
- CAREFINE PEN NEEDLES 6MM 32G
- CAREFINE PEN NEEDLES 8MM 31G
- CARETOUCH ALCOHOL 70% PREP PAD
- CARETOUCH PEN NEEDLE 29G 12MM
- CARETOUCH PEN NEEDLE 31GX1/4"
- CARETOUCH PEN NEEDLE 31GX3/16"
- CARETOUCH PEN NEEDLE 31GX5/16"
- CARETOUCH PEN NEEDLE 32GX3/16"
- CARETOUCH PEN NEEDLE 32GX5/32"
- CARETOUCH SYR 0.3 ML 31GX5/16"
- CARETOUCH SYR 0.5 ML 30GX5/16"
- CARETOUCH SYR 0.5 ML 31GX5/16"
- CARETOUCH SYR 1 ML 28GX5/16"
- CARETOUCH SYR 1 ML 29GX5/16"
- CARETOUCH SYR 1 ML 30GX5/16"
- CARETOUCH SYR 1 ML 31GX5/16"
- CLICKFINE 31G X 5/16" NEEDLES 8MM, UNIVERSAL
- CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE
- CLICKFINE UNIVERSAL 31G X 1/4" 6MM, STORE BRAND
- COMFORT EZ 0.3 ML 31G 15/64"
- COMFORT EZ 0.5 ML 31G 15/64"
- COMFORT EZ INS 0.3 ML 30GX1/2"
- COMFORT EZ INS 0.3 ML 30GX5/16"
- COMFORT EZ INS 1 ML 31G 15/64"
- COMFORT EZ INS 1 ML 31GX5/16"
- COMFORT EZ INSULIN SYR 0.3 ML
- COMFORT EZ INSULIN SYR 0.5 ML
- COMFORT EZ PEN NEEDLE 12MM 29G
- COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO
- COMFORT EZ PEN NEEDLES 4MM 33G
- COMFORT EZ PEN NEEDLES 5MM 31G MINI
- COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI
- COMFORT EZ PEN NEEDLES 5MM 33G
- COMFORT EZ PEN NEEDLES 6MM 31G
- COMFORT EZ PEN NEEDLES 6MM 32G
- COMFORT EZ PEN NEEDLES 6MM 33G
- COMFORT EZ PEN NEEDLES 8MM 31G SHORT
- COMFORT EZ PEN NEEDLES 8MM 32G
- COMFORT EZ PEN NEEDLES 8MM 33G
- COMFORT EZ PRO PEN NDL 30G 8MM
- COMFORT EZ PRO PEN NDL 31G 4MM
- COMFORT EZ PRO PEN NDL 31G 5MM
- COMFORT EZ SYR 0.3 ML 29GX1/2"
- COMFORT EZ SYR 0.5 ML 28GX1/2"
- COMFORT EZ SYR 0.5 ML 29GX1/2"
- COMFORT EZ SYR 0.5 ML 30GX1/2"

- COMFORT EZ SYR 1 ML 28GX1/2"
- COMFORT EZ SYR 1 ML 29GX1/2"
- COMFORT EZ SYR 1 ML 30GX1/2"
- COMFORT EZ SYR 1 ML 30GX5/16"
- COMFORT POINT PEN NDL 31GX1/3"
- COMFORT POINT PEN NDL 31GX1/6"
- COMFORT TOUCH PEN NDL 31G 4MM
- COMFORT TOUCH PEN NDL 31G 5MM
- COMFORT TOUCH PEN NDL 31G 6MM
- COMFORT TOUCH PEN NDL 31G 8MM
- COMFORT TOUCH PEN NDL 32G 4MM
- COMFORT TOUCH PEN NDL 32G 5MM
- COMFORT TOUCH PEN NDL 32G 6MM
- COMFORT TOUCH PEN NDL 32G 8MM
- COMFORT TOUCH PEN NDL 33G 4MM
- COMFORT TOUCH PEN NDL 33G 6MM
- COMFORT TOUCH PEN NDL 33GX5MM
- CURAD GAUZE PADS 2" X 2"
- CURITY ALCOHOL PREPS 2 PLY,MEDIUM
- CURITY GAUZE SPONGES (12 PLY)- 200/BAG
- CURITY GUAZE PADS 1'S(12 PLY)
- DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII
- DERMACEA GAUZE 2"X2" SPONGE 8 PLY
- DERMACEA NON-WOVEN 2"X2" SPNGE
- DROPLET 0.5 ML 29GX12.5MM(1/2)
- DROPLET 0.5 ML 30GX12.5MM(1/2)
- DROPLET INS 0.3 ML 29GX12.5MM
- DROPLET INS 0.3 ML 30GX12.5MM
- DROPLET INS 0.5 ML 30GX6MM(1/2)
- DROPLET INS 0.5 ML 30GX8MM(1/2)
- DROPLET INS 0.5 ML 31GX6MM(1/2)
- DROPLET INS 0.5 ML 31GX8MM(1/2)
- DROPLET INS SYR 0.3 ML 30GX6MM
- DROPLET INS SYR 0.3 ML 30GX8MM
- DROPLET INS SYR 0.3 ML 31GX6MM
- DROPLET INS SYR 0.3 ML 31GX8MM
- DROPLET INS SYR 1 ML 29GX12.5MM
- DROPLET INS SYR 1 ML 30GX12.5MM
- DROPLET INS SYR 1 ML 30GX6MM
- DROPLET INS SYR 1 ML 30GX8MM
- DROPLET INS SYR 1 ML 31GX6MM
- DROPLET INS SYR 1 ML 31GX8MM
- DROPLET MICRON 34G X 9/64"
- DROPLET PEN NEEDLE 29G 10MM
- DROPLET PEN NEEDLE 29G 12MM
- DROPLET PEN NEEDLE 30G 8MM
- DROPLET PEN NEEDLE 31G 5MM
- DROPLET PEN NEEDLE 31G 6MM
- DROPLET PEN NEEDLE 31G 8MM
- DROPLET PEN NEEDLE 32G 4MM
- DROPLET PEN NEEDLE 32G 5MM
- DROPLET PEN NEEDLE 32G 6MM
- DROPLET PEN NEEDLE 32G 8MM
- DROPSAFE ALCOHOL 70% PREP PADS
- DROPSAFE INS SYR 0.3 ML 31G 6MM
- DROPSAFE INS SYR 0.3 ML 31G 8MM
- DROPSAFE INS SYR 0.5 ML 31G 6MM
- DROPSAFE INS SYR 0.5 ML 31G 8MM
- DROPSAFE INSUL SYR 1 ML 31G 6MM
- DROPSAFE INSUL SYR 1 ML 31G 8MM
- DROPSAFE INSULN 1 ML 29G 12.5MM
- DROPSAFE PEN NEEDLE 31GX1/4"
- DROPSAFE PEN NEEDLE 31GX3/16"
- DROPSAFE PEN NEEDLE 31GX5/16"
- DRUG MART ULTRA COMFORT SYR
- EASY CMFT SFTY PEN NDL 31G 5MM
- EASY CMFT SFTY PEN NDL 31G 6MM

- EASY CMFT SFTY PEN NDL 32G 4MM
- EASY COMFORT 0.3 ML 31G 1/2"
- EASY COMFORT 0.3 ML 31G 5/16"
- EASY COMFORT 0.3 ML SYRINGE
- EASY COMFORT 0.5 ML 30GX1/2"
- EASY COMFORT 0.5 ML 31GX5/16"
- EASY COMFORT 0.5 ML 32GX5/16"
- EASY COMFORT 0.5 ML SYRINGE
- EASY COMFORT 1 ML 31GX5/16"
- EASY COMFORT 1 ML 32GX5/16"
- EASY COMFORT ALCOHOL 70% PAD
- EASY COMFORT INSULIN 1 ML SYR
- EASY COMFORT PEN NDL 31GX1/4"
- EASY COMFORT PEN NDL 31GX3/16"
- EASY COMFORT PEN NDL 31GX5/16"
- EASY COMFORT PEN NDL 32GX5/32"
- EASY COMFORT PEN NDL 33G 4MM
- EASY COMFORT PEN NDL 33G 5MM
- EASY COMFORT PEN NDL 33G 6MM
- EASY COMFORT SYR 1 ML 30GX1/2"
- EASY GLIDE INS 0.3 ML 31GX6MM
- EASY GLIDE INS 0.5 ML 31GX6MM
- EASY GLIDE INS 1 ML 31GX6MM
- EASY GLIDE PEN NEEDLE 4MM 33G
- EASY TOUCH 0.3 ML SYR 30GX1/2"
- EASY TOUCH 0.5 ML SYR 27GX1/2"
- EASY TOUCH 0.5 ML SYR 29GX1/2"
- EASY TOUCH 0.5 ML SYR 30GX1/2"
- EASY TOUCH 0.5 ML SYR 30GX5/16
- EASY TOUCH 1 ML SYR 27GX1/2"
- EASY TOUCH 1 ML SYR 29GX1/2"
- EASY TOUCH 1 ML SYR 30GX1/2"
- EASY TOUCH ALCOHOL 70% PADS GAMMA-STERILIZED
- EASY TOUCH FLIPLK 1 ML 27GX0.5
- EASY TOUCH INSULIN 1 ML 29GX1/2
- EASY TOUCH INSULIN 1 ML 30GX1/2
- EASY TOUCH INSULIN SYR 0.3 ML
- EASY TOUCH INSULIN SYR 0.5 ML
- EASY TOUCH INSULIN SYR 1 ML
- EASY TOUCH INSULIN SYR 1 ML RETRACTABLE
- EASY TOUCH INSULN 1 ML 29GX1/2"
- EASY TOUCH INSULN 1 ML 30GX1/2"
- EASY TOUCH INSULN 1 ML 30GX5/16
- EASY TOUCH INSULN 1 ML 31GX5/16
- EASY TOUCH LUER LOK INSUL 1 ML
- EASY TOUCH PEN NEEDLE 29GX1/2"
- EASY TOUCH PEN NEEDLE 30GX5/16
- EASY TOUCH PEN NEEDLE 31GX1/4"
- EASY TOUCH PEN NEEDLE 31GX3/16
- EASY TOUCH PEN NEEDLE 31GX5/16
- EASY TOUCH PEN NEEDLE 32GX1/4"
- EASY TOUCH PEN NEEDLE 32GX3/16
- EASY TOUCH PEN NEEDLE 32GX5/32
- EASY TOUCH SAF PEN NDL 29G 5MM
- EASY TOUCH SAF PEN NDL 29G 8MM
- EASY TOUCH SAF PEN NDL 30G 5MM
- EASY TOUCH SAF PEN NDL 30G 8MM
- EASY TOUCH SYR 0.5 ML 28G 12.7MM
- EASY TOUCH SYR 0.5 ML 29G 12.7MM
- EASY TOUCH SYR 1 ML 27G 16MM
- EASY TOUCH SYR 1 ML 28G 12.7MM
- EASY TOUCH SYR 1 ML 29G 12.7MM
- EASY TOUCH UNI-SLIP SYR 1 ML
- EASYTOUCH SAF PEN NDL 30G 6MM
- EMBRACE PEN NEEDLE 29G 12MM
- EMBRACE PEN NEEDLE 30G 5MM
- EMBRACE PEN NEEDLE 30G 8MM
- EMBRACE PEN NEEDLE 31G 5MM
- EMBRACE PEN NEEDLE 31G 6MM
- EMBRACE PEN NEEDLE 31G 8MM
- EMBRACE PEN NEEDLE 32G 4MM
- EQL INSULIN 0.3 ML SYRINGE SHORT NEEDLE
- EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE
- EQL INSULIN 1 ML SYRINGE SHORT NEEDLE
- FIFTY50 INS 0.5 ML 31GX5/16" SHORT NEEDLE (OTC)
- FIFTY50 PEN 31G X 3/16" NEEDLE (OTC)
- FP INSULIN 1 ML SYRINGE
- FREESTYLE PREC 0.5 ML 30GX5/16

- FREESTYLE PREC 0.5 ML 31GX5/16
- FREESTYLE PREC 1 ML 30GX5/16"
- FREESTYLE PREC 1 ML 31GX5/16"
- GAUZE PAD TOPICAL BANDAGE 2 X 2 "
- GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT
- GNP ULTRA COMFORT 0.5 ML SYR
- GNP ULTRA COMFORT 1 ML SYRINGE
- GNP ULTRA COMFORT 3/10 ML SYR
- HEALTHWISE INS 0.3 ML 30GX5/16"
- HEALTHWISE INS 0.3 ML 31GX5/16"
- HEALTHWISE INS 0.5 ML 30GX5/16"
- HEALTHWISE INS 0.5 ML 31GX5/16"
- HEALTHWISE INS 1 ML 30GX5/16"
- HEALTHWISE INS 1 ML 31GX5/16"
- HEALTHWISE PEN NEEDLE 31G 5MM
- HEALTHWISE PEN NEEDLE 31G 8MM
- HEALTHWISE PEN NEEDLE 32G 4MM
- HEALTHY ACCENTS PENTIP 4MM 32G
- HEALTHY ACCENTS PENTIP 5MM 31G
- HEALTHY ACCENTS PENTIP 6MM 31G
- HEALTHY ACCENTS PENTIP 8MM 31G
- HEALTHY ACCENTS PENTIP 12MM 29G
- HEB INCONTROL ALCOHOL 70% PADS
- INCONTROL PEN NEEDLE 12MM 29G
- INCONTROL PEN NEEDLE 4MM 32G
- INCONTROL PEN NEEDLE 5MM 31G
- INCONTROL PEN NEEDLE 6MM 31G
- INCONTROL PEN NEEDLE 8MM 31G
- INSULIN SYR 0.3 ML 31GX1/4(1/2)
- INSULIN SYRIN 0.5 ML 28GX1/2" (OTC)
- INSULIN SYRIN 0.5 ML 29GX1/2" (OTC)
- INSULIN SYRIN 0.5 ML 30GX1/2" SHORT NEEDLE (OTC)
- INSULIN SYRIN 0.5 ML 30GX5/16" SHORT NEEDLE (OTC)
- INSULIN SYRING 0.5 ML 27G 1/2" OUTER
- INSULIN SYRINGE 0.3 ML
- INSULIN SYRINGE 0.3 ML 31GX1/4
- INSULIN SYRINGE 0.5 ML
- INSULIN SYRINGE 0.5 ML 31GX1/4
- INSULIN SYRINGE 1 ML
- INSULIN SYRINGE 1 ML 27G 1/2" INNER
- INSULIN SYRINGE 1 ML 27G 16MM
- INSULIN SYRINGE 1 ML 28GX1/2" (OTC)
- INSULIN SYRINGE 1 ML 30GX1/2" (RX)
- INSULIN SYRINGE 1 ML 30GX5/16" SHORT NEEDLE (OTC)
- INSULIN SYRINGE 1 ML 31GX1/4"
- INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE
- INSUPEN 30G ULTRAFIN NEEDLE
- INSUPEN 31G ULTRAFIN NEEDLE
- INSUPEN 32G 6MM PEN NEEDLE
- INSUPEN 32G 8MM PEN NEEDLE
- INSUPEN PEN NEEDLE 29GX12MM
- INSUPEN PEN NEEDLE 31GX3/16"
- INSUPEN PEN NEEDLE 32GX4MM
- INSUPEN PEN NEEDLE 33GX4MM
- IV ANTISEPTIC WIPES
- KENDALL ALCOHOL 70% PREP PAD
- LISCO SPONGES 100/BAG
- LITE TOUCH 31GX1/4" PEN NEEDLE
- LITE TOUCH INSULIN 0.5 ML SYR
- LITE TOUCH INSULIN 1 ML SYR
- LITE TOUCH INSULIN SYR 1 ML
- LITE TOUCH PEN NEEDLE 29G
- LITE TOUCH PEN NEEDLE 31G
- LITETOUCH INS 0.3 ML 29GX1/2"
- LITETOUCH INS 0.3 ML 30GX5/16"
- LITETOUCH INS 0.3 ML 31GX5/16"
- LITETOUCH INS 0.5 ML 31GX5/16"
- LITETOUCH SYR 0.5 ML 28GX1/2"

- LITETOUCH SYR 0.5 ML 29GX1/2"
- LITETOUCH SYR 0.5 ML 30GX5/16"
- LITETOUCH SYRIN 1 ML 28GX1/2"
- LITETOUCH SYRIN 1 ML 29GX1/2"
- LITETOUCH SYRIN 1 ML 30GX5/16"
- MAGELLAN INSUL SYRINGE 0.3 ML
- MAGELLAN INSUL SYRINGE 0.5 ML
- MAGELLAN INSULIN SYR 0.3 ML
- MAGELLAN INSULIN SYR 0.5 ML
- MAGELLAN INSULIN SYRINGE 1 ML
- MAXI-COMFORT INS 0.5 ML 28G
- MAXI-COMFORT INS 1 ML 28GX1/2"
- MAXICOMFORT II PEN NDL 31GX6MM
- MAXICOMFORT INS 0.5 ML 27GX1/2"
- MAXICOMFORT INS 1 ML 27GX1/2"
- MAXICOMFORT PEN NDL 29G X 5MM
- MAXICOMFORT PEN NDL 29G X 8MM
- MICRODOT PEN NEEDLE 31GX6MM
- MICRODOT PEN NEEDLE 32GX4MM
- MICRODOT PEN NEEDLE 33GX4MM
- MICRODOT READYGARD NDL 31G 5MM OUTER
- MINI PEN NEEDLE 32G 4MM
- MINI PEN NEEDLE 32G 5MM
- MINI PEN NEEDLE 32G 6MM
- MINI PEN NEEDLE 32G 8MM
- MINI PEN NEEDLE 33G 4MM
- MINI PEN NEEDLE 33G 5MM
- MINI PEN NEEDLE 33G 6MM
- MINI ULTRA-THIN II PEN NDL 31G STERILE
- MONOJECT 0.5 ML SYRN 28GX1/2"
- MONOJECT 1 ML SYRN 27X1/2"
- MONOJECT 1 ML SYRN 28GX1/2" (OTC)
- MONOJECT INSUL SYR U100 (OTC)
- MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC)
- MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC)
- MONOJECT INSUL SYR U100 1 ML
- MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC)
- MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC)
- MONOJECT INSULIN SYR 0.3 ML
- MONOJECT INSULIN SYR 0.3 ML (OTC)
- MONOJECT INSULIN SYR 0.5 ML
- MONOJECT INSULIN SYR 0.5 ML (OTC)
- MONOJECT INSULIN SYR 1 ML 3'S (OTC)
- MONOJECT INSULIN SYR U-100
- MONOJECT SYRINGE 0.3 ML
- MONOJECT SYRINGE 0.5 ML
- MONOJECT SYRINGE 1 ML
- NOVOFINE 30
- NOVOFINE 32G NEEDLES
- NOVOFINE PLUS PEN NDL 32GX1/6"
- NOVOTWIST NEEDLE 32G 5MM
- PC UNIFINE PENTIPS 8MM NEEDLE SHORT
- PEN NEEDLE 30G 5MM OUTER
- PEN NEEDLE 30G 8MM INNER
- PEN NEEDLE 30G X 5/16"
- PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2"
- PEN NEEDLES 12MM 29G 29GX12MM,STRL
- PEN NEEDLES 4MM 32G
- PEN NEEDLES 6MM 31G 31GX6MM, STRL
- PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC)
- PENTIPS PEN NEEDLE 29G 1/2"
- PENTIPS PEN NEEDLE 31G 1/4"
- PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM
- PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM
- PENTIPS PEN NEEDLE 32G 1/4"
- PENTIPS PEN NEEDLE 32GX5/32" 4MM
- PIP PEN NEEDLE 31G X 5MM
- PIP PEN NEEDLE 32G X 4MM
- PREVENT PEN NEEDLE 31GX1/4"
- PREVENT PEN NEEDLE 31GX5/16"
- PRO COMFORT 0.5 ML 30GX1/2"

- PRO COMFORT 0.5 ML 30GX5/16"
- PRO COMFORT 0.5 ML 31GX5/16"
- PRO COMFORT 1 ML 30GX1/2"
- PRO COMFORT 1 ML 30GX5/16"
- PRO COMFORT 1 ML 31GX5/16"
- PRO COMFORT ALCOHOL 70% PADS
- PRO COMFORT PEN ND L 31GX5/16"
- PRO COMFORT PEN ND L 32G X 1/4"
- PRO COMFORT PEN ND L 4MM 32G
- PRO COMFORT PEN ND L 5MM 32G
- PRODIGY INS SYR 1 ML 28GX1/2"
- PRODIGY SYRNG 0.5 ML 31GX5/16"
- PRODIGY SYRNGE 0.3 ML 31GX5/16"
- PURE CMFT SFTY PEN ND L 31G 5MM
- PURE CMFT SFTY PEN ND L 31G 6MM
- PURE CMFT SFTY PEN ND L 32G 4MM
- PURE COMFORT ALCOHOL 70% PADS
- PURE COMFORT PEN ND L 32G 4MM
- PURE COMFORT PEN ND L 32G 5MM
- PURE COMFORT PEN ND L 32G 6MM
- PURE COMFORT PEN ND L 32G 8MM
- RAYA SURE PEN NEEDLE 29G 12MM
- RAYA SURE PEN NEEDLE 31G 4MM
- RAYA SURE PEN NEEDLE 31G 5MM
- RAYA SURE PEN NEEDLE 31G 6MM
- RELI-ON INSULIN 0.5 ML SYR
- RELI-ON INSULIN 1 ML SYR
- RELION INS SYR 0.3 ML 31GX6MM
- RELION INS SYR 0.5 ML 31GX6MM
- RELION INS SYR 1 ML 31GX15/64"
- RELION MINI PEN 31G X 1/4" ND L
- SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10
- SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10
- SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10
- SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10
- SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10
- SAFETY PEN NEEDLE 31G 4MM
- SAFETY PEN NEEDLE 5MM X 31G
- SAFETY SYRINGE 0.5 ML 30G 1/2"
- SECURES SAFE PEN ND L 30GX5/16" OUTER
- SECURES SAFE SYR 0.5 ML 29G 1/2" OUTER
- SECURES SAFE SYRNG 1 ML 29G 1/2" OUTER
- SKY SAFETY PEN NEEDLE 30G 5MM
- SKY SAFETY PEN NEEDLE 30G 8MM
- SM ULT CFT 0.3 ML 31GX5/16(1/2)
- STERILE PADS 2" X 2"
- SURE CMFT SFTY PEN ND L 31G 6MM
- SURE CMFT SFTY PEN ND L 32G 4MM
- SURE COMFORT 0.5 ML SYRINGE
- SURE COMFORT 1 ML SYRINGE
- SURE COMFORT 3/10 ML SYRINGE
- SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE
- SURE COMFORT 30G PEN NEEDLE
- SURE COMFORT ALCOHOL PREP PADS
- SURE COMFORT INS 0.3 ML 31GX1/4
- SURE COMFORT INS 0.5 ML 31GX1/4
- SURE COMFORT INS 1 ML 31GX1/4"
- SURE COMFORT PEN ND L 29GX1/2" 12.7MM
- SURE COMFORT PEN ND L 31G 5MM
- SURE COMFORT PEN ND L 31G 8MM
- SURE COMFORT PEN ND L 32G 4MM
- SURE COMFORT PEN ND L 32G 6MM
- SURE-FINE PEN NEEDLES 12.7MM
- SURE-FINE PEN NEEDLES 5MM
- SURE-FINE PEN NEEDLES 8MM
- SURE-JECT INSU SYR U100 0.3 ML
- SURE-JECT INSU SYR U100 0.5 ML
- SURE-JECT INSU SYR U100 1 ML
- SURE-JECT INSUL SYR U100 1 ML
- SURE-JECT INSULIN SYRINGE 1 ML
- SURE-PREP ALCOHOL PREP PADS
- TECHLITE 0.3 ML 29GX12MM (1/2)
- TECHLITE 0.3 ML 30GX12MM (1/2)
- TECHLITE 0.3 ML 30GX8MM (1/2)
- TECHLITE 0.3 ML 31GX6MM (1/2)
- TECHLITE 0.3 ML 31GX8MM (1/2)
- TECHLITE 0.5 ML 30GX12MM (1/2)
- TECHLITE 0.5 ML 30GX8MM (1/2)
- TECHLITE 0.5 ML 31GX6MM (1/2)

- TECHLITE 0.5 ML 31GX8MM (1/2)
- TECHLITE INS SYR 1 ML 29GX12MM
- TECHLITE INS SYR 1 ML 30GX12MM
- TECHLITE INS SYR 1 ML 30GX8MM
- TECHLITE INS SYR 1 ML 31GX6MM
- TECHLITE INS SYR 1 ML 31GX8MM
- TECHLITE PEN NEEDLE 29GX1/2"
- TECHLITE PEN NEEDLE 29GX3/8"
- TECHLITE PEN NEEDLE 31GX1/4"
- TECHLITE PEN NEEDLE 31GX3/16"
- TECHLITE PEN NEEDLE 31GX5/16"
- TECHLITE PEN NEEDLE 32GX1/4"
- TECHLITE PEN NEEDLE 32GX5/16"
- TECHLITE PEN NEEDLE 32GX5/32"
- TECHLITE PLUS PEN NDL 32G 4MM
- TERUMO INS SYRINGE U100-1 ML
- TERUMO INS SYRINGE U100-1/2 ML
- TERUMO INS SYRINGE U100-1/3 ML
- TERUMO INS SYRNG U100-1/2 ML
- THINPRO INS SYRIN U100-0.3 ML
- THINPRO INS SYRIN U100-0.5 ML
- THINPRO INS SYRIN U100-1 ML
- TOPCARE CLICKFINE 31G X 1/4"
- TOPCARE CLICKFINE 31G X 5/16"
- TOPCARE ULTRA COMFORT SYRINGE
- TRUE CMFRT PRO 0.5 ML 30G 5/16"
- TRUE CMFRT PRO 0.5 ML 31G 5/16"
- TRUE CMFRT PRO 0.5 ML 32G 5/16"
- TRUE CMFT SFTY PEN NDL 31G 5MM
- TRUE CMFT SFTY PEN NDL 31G 6MM
- TRUE CMFT SFTY PEN NDL 32G 4MM
- TRUE COMFORT 0.5 ML 30G 1/2"
- TRUE COMFORT 0.5 ML 30G 5/16"
- TRUE COMFORT 0.5 ML 31G 5/16"
- TRUE COMFORT 0.5 ML 31GX5/16"
- TRUE COMFORT 1 ML 31GX5/16"
- TRUE COMFORT ALCOHOL 70% PADS
- TRUE COMFORT PEN NDL 31G 8MM
- TRUE COMFORT PEN NDL 31GX5MM
- TRUE COMFORT PEN NDL 31GX6MM
- TRUE COMFORT PEN NDL 32G 5MM
- TRUE COMFORT PEN NDL 32G 6MM
- TRUE COMFORT PEN NDL 32GX4MM
- TRUE COMFORT PEN NDL 33G 4MM
- TRUE COMFORT PEN NDL 33G 5MM
- TRUE COMFORT PEN NDL 33G 6MM
- TRUE COMFORT PRO 1 ML 30G 1/2"
- TRUE COMFORT PRO 1 ML 30G 5/16"
- TRUE COMFORT PRO 1 ML 31G 5/16"
- TRUE COMFORT PRO 1 ML 32G 5/16"
- TRUE COMFORT PRO ALCOHOL PADS
- TRUE COMFORT SFTY 1 ML 30G 1/2"
- TRUE COMFRT PRO 0.5 ML 30G 1/2"
- TRUE COMFRT SFTY 1 ML 30G 5/16"
- TRUE COMFRT SFTY 1 ML 31G 5/16"
- TRUE COMFRT SFTY 1 ML 32G 5/16"
- TRUEPLUS PEN NEEDLE 29GX1/2"
- TRUEPLUS PEN NEEDLE 31G X 1/4"
- TRUEPLUS PEN NEEDLE 31GX3/16"
- TRUEPLUS PEN NEEDLE 31GX5/16"
- TRUEPLUS PEN NEEDLE 32GX5/32"
- TRUEPLUS SYR 0.3 ML 29GX1/2"
- TRUEPLUS SYR 0.3 ML 30GX5/16"
- TRUEPLUS SYR 0.3 ML 31GX5/16"
- TRUEPLUS SYR 0.5 ML 28GX1/2"
- TRUEPLUS SYR 0.5 ML 29GX1/2"
- TRUEPLUS SYR 0.5 ML 30GX5/16"
- TRUEPLUS SYR 0.5 ML 31GX5/16"
- TRUEPLUS SYR 1 ML 28GX1/2"
- TRUEPLUS SYR 1 ML 29GX1/2"
- TRUEPLUS SYR 1 ML 30GX5/16"
- TRUEPLUS SYR 1 ML 31GX5/16"
- ULTICAR INS 0.3 ML 31GX1/4(1/2)
- ULTICARE INS 1 ML 31GX1/4"
- ULTICARE INS SYR 0.3 ML 30G 8MM
- ULTICARE INS SYR 0.3 ML 31G 6MM
- ULTICARE INS SYR 0.3 ML 31G 8MM
- ULTICARE INS SYR 0.5 ML 31G 6MM
- ULTICARE INS SYR 1 ML 30GX1/2"
- ULTICARE PEN NEEDLE 31GX3/16"
- ULTICARE PEN NEEDLE 6MM 31G
- ULTICARE PEN NEEDLE 8MM 31G
- ULTICARE PEN NEEDLES 12MM 29G
- ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM
- ULTICARE PEN NEEDLES 6MM 32G

- ULTICARE SAFE PEN NDL 30G 8MM
- ULTICARE SAFE PEN NDL 5MM 30G
- ULTICARE SYR 0.3 ML 29G 12.7MM
- ULTICARE SYR 0.3 ML 30GX1/2"
- ULTICARE SYR 0.3 ML 31GX5/16"
SHORT NDL
- ULTICARE SYR 0.5 ML 30GX1/2"
- ULTICARE SYR 0.5 ML 31GX5/16"
SHORT NDL
- ULTICARE SYR 1 ML 31GX5/16"
- ULTIGUARD SAFE 1 ML 30G 12.7MM
- ULTIGUARD SAFE0.3 ML 30G
12.7MM
- ULTIGUARD SAFE0.5 ML 30G
12.7MM
- ULTIGUARD SAFEPACK 1 ML 31G
8MM
- ULTIGUARD SAFEPACK 29G 12.7MM
- ULTIGUARD SAFEPACK 31G 5MM
- ULTIGUARD SAFEPACK 31G 6MM
- ULTIGUARD SAFEPACK 31G 8MM
- ULTIGUARD SAFEPACK 32G 4MM
- ULTIGUARD SAFEPACK 32G 6MM
- ULTIGUARD SAFEPK 0.3 ML 31G
8MM
- ULTIGUARD SAFEPK 0.5 ML 31G
8MM
- ULTILET ALCOHOL STERL SWAB
- ULTILET INSULIN SYRINGE 0.3 ML
- ULTILET INSULIN SYRINGE 0.5 ML
- ULTILET INSULIN SYRINGE 1 ML
- ULTILET PEN NEEDLE
- ULTILET PEN NEEDLE 4MM 32G
- ULTRA COMFORT 0.3 ML SYRINGE
- ULTRA COMFORT 0.5 ML 28GX1/2"
CONVERTS TO 29G
- ULTRA COMFORT 0.5 ML 29GX1/2"
- ULTRA COMFORT 0.5 ML SYRINGE
- ULTRA COMFORT 1 ML 31GX5/16"
- ULTRA COMFORT 1 ML SYRINGE
- ULTRA FLO 0.3 ML 30G 1/2" (1/2)
- ULTRA FLO 0.3 ML 30G 5/16"(1/2)
- ULTRA FLO 0.3 ML 31G 5/16"(1/2)
- ULTRA FLO PEN NEEDLE 31G 5MM
- ULTRA FLO PEN NEEDLE 31G 8MM
- ULTRA FLO PEN NEEDLE 32G 4MM
- ULTRA FLO PEN NEEDLE 33G 4MM
- ULTRA FLO PEN NEEDLES 12MM
29G
- ULTRA FLO SYR 0.3 ML 29GX1/2"
- ULTRA FLO SYR 0.3 ML 30G 5/16"
- ULTRA FLO SYR 0.3 ML 31G 5/16"
- ULTRA FLO SYR 0.5 ML 29G 1/2"
- ULTRA THIN PEN NDL 32G X 4MM
- ULTRA-FINE 0.3 ML 31G 6MM (1/2)
- ULTRA-FINE 0.3 ML 31G 8MM (1/2)
- ULTRA-FINE PEN NDL 29G 12.7MM
- ULTRA-FINE PEN NEEDLE 32G 6MM
- ULTRA-THIN II 1 ML 31GX5/16"
- ULTRA-THIN II INS 0.3 ML 30G
- ULTRA-THIN II INS 0.3 ML 31G
- ULTRA-THIN II INS 0.5 ML 29G
- ULTRA-THIN II INS 0.5 ML 30G
- ULTRA-THIN II INS 0.5 ML 31G
- ULTRA-THIN II INS SYR 1 ML 29G
- ULTRA-THIN II INS SYR 1 ML 30G
- ULTRA-THIN II PEN NDL 29GX1/2"
- ULTRA-THIN II PEN NDL 31GX5/16"
- ULTRACARE INS 0.3 ML 30GX5/16"
- ULTRACARE INS 0.3 ML 31GX5/16"
- ULTRACARE INS 0.5 ML 30GX1/2"
- ULTRACARE INS 0.5 ML 30GX5/16"
- ULTRACARE INS 0.5 ML 31GX5/16"
- ULTRACARE INS 0.5 ML 31GX5/16"
- ULTRACARE INS 1 ML 30G X 5/16"
- ULTRACARE INS 1 ML 30GX1/2"
- ULTRACARE INS 1 ML 31G X 5/16"
- ULTRACARE PEN NEEDLE 31GX1/4"
- ULTRACARE PEN NEEDLE 31GX3/16"
- ULTRACARE PEN NEEDLE 31GX5/16"
- ULTRACARE PEN NEEDLE 32GX1/4"
- ULTRACARE PEN NEEDLE 32GX3/16"
- ULTRACARE PEN NEEDLE 32GX5/32"
- ULTRACARE PEN NEEDLE 33GX5/32"
- UNIFINE PEN NEEDLE 32G 4MM
- UNIFINE PENTIPS 12MM 29G
29GX12MM, STRL
- UNIFINE PENTIPS 31GX3/16"
31GX5MM,STRL,MINI
- UNIFINE PENTIPS 32GX1/4"
- UNIFINE PENTIPS 32GX5/32"
32GX4MM, STRL, NANO
- UNIFINE PENTIPS 33GX5/32"

- UNIFINE PENTIPS 6MM 31G
- UNIFINE PENTIPS MAX 30GX3/16"
- UNIFINE PENTIPS NEEDLES 29G
- UNIFINE PENTIPS PLUS 29GX1/2" 12MM
- UNIFINE PENTIPS PLUS 30GX3/16"
- UNIFINE PENTIPS PLUS 31GX1/4" ULTRA SHORT, 6MM
- UNIFINE PENTIPS PLUS 31GX3/16" MINI
- UNIFINE PENTIPS PLUS 31GX5/16" SHORT
- UNIFINE PENTIPS PLUS 32GX5/32"
- UNIFINE PENTIPS PLUS 33GX5/32"
- UNIFINE PROTECT 30G 5MM
- UNIFINE PROTECT 30G 8MM
- UNIFINE PROTECT 32G 4MM
- UNIFINE SAFECONTROL 30G 5MM
- UNIFINE SAFECONTROL 30G 8MM
- UNIFINE SAFECONTROL 31G 5MM
- UNIFINE SAFECONTROL 31G 6MM
- UNIFINE SAFECONTROL 31G 8MM
- UNIFINE SAFECONTROL 32G 4MM
- UNIFINE ULTRA PEN NDL 31G 5MM
- UNIFINE ULTRA PEN NDL 31G 6MM
- UNIFINE ULTRA PEN NDL 31G 8MM
- UNIFINE ULTRA PEN NDL 32G 4MM
- VANISHPOINT 0.5 ML 30GX1/2" SY OUTER
- VANISHPOINT INS 1 ML 30GX3/16"
- VANISHPOINT U-100 29X1/2 SYR
- VERIFINE INS SYR 1 ML 29G 1/2"
- VERIFINE PEN NEEDLE 29G 12MM
- VERIFINE PEN NEEDLE 31G 5MM
- VERIFINE PEN NEEDLE 31G X 6MM
- VERIFINE PEN NEEDLE 31G X 8MM
- VERIFINE PEN NEEDLE 32G 6MM
- VERIFINE PEN NEEDLE 32G X 4MM
- VERIFINE PEN NEEDLE 32G X 5MM
- VERIFINE PLUS PEN NDL 31G 5MM
- VERIFINE PLUS PEN NDL 31G 8MM
- VERIFINE PLUS PEN NDL 32G 4MM
- VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER
- VERIFINE SYRING 0.5 ML 29G 1/2"
- VERIFINE SYRING 1 ML 31G 5/16"
- VERIFINE SYRNG 0.3 ML 31G 5/16"
- VERIFINE SYRNG 0.5 ML 31G 5/16"
- VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY
- WEBCOL ALCOHOL PREPS 20'S,LARGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | LIFETIME |
| Other Criteria | |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

INTERFERON BETA-1A

Products Affected

- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML
- REBIF (WITH ALBUMIN)
- REBIF REBIDOSE
- REBIF TITRATION PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INVEGA HAFYERA

Products Affected

- INVEGA HAFYERA

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to all of the formulary alternatives: oral paliperidone and Invega Sustenna. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INVEGA SUSTENNA

Products Affected

- INVEGA SUSTENNA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to the formulary alternative: oral paliperidone. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INVEGA TRINZA

Products Affected

- INVEGA TRINZA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to all of the formulary alternatives: oral paliperidone and Invega Sustenna. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ITRACONAZOLE

Products Affected

- *itraconazole oral solution*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

JYLAMVO

Products Affected

- JYLAMVO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Oncologist, Dermatologist, Hematologist , Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

KALYDECO

Products Affected

- KALYDECO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor. |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist, Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

KERENDIA

Products Affected

- KERENDIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with a strong CYP3A4 inhibitor or diagnosis of adrenal insufficiency |
| Required Medical Information | Labs within the past 30 days documenting serum potassium level of less than or equal to 5.0 mEq/L, estimated glomerular filtration rate of at least 25 mL/min/1.73m ² and urine albumin-to-creatinine ratio (UACR) of at least 30 mg/g (2) Receiving concurrent therapy with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) at maximally tolerated labeled dosage, unless contraindicated (3) medical justification that a sodium-glucose cotransport-2 (SGLT2) inhibitor (Jardiance, Invokana, Farxiga, Steglatro) AND a steroidal mineralocorticoid receptor antagonist (spironolactone, eplerenone) have been tried and failed, are contraindicated, or would not be medically appropriate for the patient. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

KINERET

Products Affected

- KINERET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Rheumatoid Arthritis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Rinvoq, or Xeljanz IR/XR. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

KORLYM

Products Affected

- KORLYM
- *mifepristone oral tablet 300 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use of simvastatin, lovastatin and CYP3A substrates with narrow therapeutic ranges (e.g. cyclosporine, fentanyl, sirolimus, etc.). History of unexplained vaginal bleeding or endometrial hyperplasia with atypia or endometrial carcinoma. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEDIPASVIR-SOFOSBUVIR

Products Affected

- *ledipasvir-sofosbuvir*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines. |
| Age Restrictions | |
| Prescriber Restrictions | Gastroenterologist, Hepatologist, Infectious Disease specialist |
| Coverage Duration | Duration will be applied consistent with current AASLD/IDSA guidance. |
| Other Criteria | Hepatitis C: Failure or clinically significant adverse effects to the formulary alternative: sofosbuvir-velpatasvir (generic Epclusa). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEUKINE

Products Affected

- LEUKINE INJECTION RECON SOLN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Excessive leukemia myeloid blasts in the bone marrow or peripheral blood equal to or greater than 10%. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hematologist, Oncologist |
| Coverage Duration | 3 months. |
| Other Criteria | Failure or clinically significant adverse effects to formulary alternative: Nivestym and Zarxio. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEUPROLIDE ACETATE

Products Affected

- *leuprolide (3 month)*
- *leuprolide subcutaneous kit*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Oncologist, Urologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LEVALBUTEROL

Products Affected

- *levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: albuterol inhalant solution. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LIDOCAINE PATCH

Products Affected

- *lidocaine topical adhesive patch, medicated 5 %*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of one of the following: Pain associated with diabetic neuropathy, Pain associated with cancer-related neuropathy, Post-herpetic neuralgia, Chronic back pain, or Osteoarthritis of the knee or hip. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LIVTENCITY

Products Affected

- LIVTENCITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | New: Documentation that patient is refractory to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet. |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist, Oncologist, Transplant specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LUPRON DEPOT

Products Affected

- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Endometriosis: Patient has had surgical ablation to prevent recurrence, or history of failure, contraindication, or intolerance to oral contraceptives. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

LYRICA

Products Affected

- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Postherpetic neuralgia: Failure or clinically significant adverse effects to the formulary alternative: gabapentin. Diabetic neuropathy: Failure or clinically significant adverse effects to all of the formulary alternatives: duloxetine and gabapentin. Fibromyalgia: Failure or clinically significant adverse effects to two of the formulary alternatives: duloxetine, gabapentin or Savella. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MEGESTROL

Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml)*
- *megestrol oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Cachexia associated with AIDS: Failure or clinically significant adverse effects to all of the formulary alternatives: dronabinol and oxandrolone. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MEPROBAMATE

Products Affected

- *meprobamate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to at least two of the formulary alternatives: buspirone, duloxetine, escitalopram, or venlafaxine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

METHOCARBAMOL

Products Affected

- *methocarbamol oral tablet 500 mg, 750 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Documentation explaining specific benefit established with the medication, and how that benefit outweighs the potential risk |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

METHYLDOPA/HYDROCHLOROTHIAZIDE

Products Affected

- *methyldopa-hydrochlorothiazide*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: benazepril, fosinopril, hydrochlorothiazide, irbesartan, lisinopril, losartan, losartan/hydrochlorothiazide, lisinopril/hydrochlorothiazide, quinapril/hydrochlorothiazide, quinapril, ramipril, or valsartan/hydrochlorothiazide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

METYROSINE

Products Affected

- *metyrosine*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | Essential hypertension. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

MODAFINIL

Products Affected

- *modafinil*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Narcolepsy: Failure or clinically significant adverse effects to all of the formulary alternatives: dextroamphetamine and methylphenidate. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NAYZILAM

Products Affected

- LIBERVANT
- NAYZILAM

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NIVESTYM

Products Affected

- NIVESTYM INJECTION

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hematologist, Infectious Disease specialist, Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NUCALA

Products Affected

- NUCALA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Allergist, Immunologist, Pulmonologist, Rheumatologist, Hematologist, or Otolaryngologist. |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Asthma: Failure or clinically significant adverse effects to two of the formulary alternatives: 1) budesonide, Flovent, Arnuity Ellipta or Qvar and 2) fluticasone-salmeterol, Wixela, or Breo Ellipta. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NUEDEXTA

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

NUPLAZID

Products Affected

- NUPLAZID

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OCTREOTIDE

Products Affected

- *octreotide acetate injection solution*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OFEV

Products Affected

- OFEV

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Moderate or severe hepatic impairment (Child-Pugh B or C). |
| Required Medical Information | Initial authorization: Documentation of liver function tests. Reauthorization only: Documentation of positive response to therapy and documentation of liver function tests. |
| Age Restrictions | |
| Prescriber Restrictions | Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OLANZAPINE ODT

Products Affected

- *olanzapine oral tablet, disintegrating*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of difficulty or inability to swallow or failure or clinically significant adverse effects to the formulary alternative: oral olanzapine. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OLANZAPINE SOLUTION

Products Affected

- *olanzapine intramuscular*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OMNITROPE

Products Affected

- OMNITROPE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | AGHD (initial): diagnosis confirmed as a result of past diagnosis of childhood-onset GHD, or adult-onset GHD with documentation of hormone deficiency due to hypothalamic-pituitary disease from organic or known causes (eg: damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and documentation of one growth-hormone stimulant test (eg: insulin tolerance test, arginine/GHRH, glucagon, arginine) to confirm adult GHD w/corresponding peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or documented deficiency of 3 anterior pituitary hormones (prolactin, ACTH, TSH, FSH/LH) and IFG-1/somatomedin C below age and gender adjusted normal range as provided by physicians lab. AGHD (reauthorization): Documentation of positive experience by the patient. |
| Age Restrictions | |
| Prescriber Restrictions | Endocrinologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ORAL ANTIPSYCHOTICS

Products Affected

- *asenapine maleate*
- CAPLYTA
- COBENFY
- COBENFY STARTER PACK
- FANAPT
- LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG
- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*
- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE,DOSE PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ORENCIA

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Rheumatologist, transplant specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ORKAMBI

Products Affected

- ORKAMBI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of homozygous F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist, Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OTEZLA

Products Affected

- OTEZLA
- OTEZLA STARTER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Plaque psoriasis: documentation of psoriasis with BSA of 2% or greater or affecting crucial body areas such as hands, feet, face or genitals. |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OXERVATE

Products Affected

- OXERVATE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of Stage 2 or 3 neurotrophic keratitis. |
| Age Restrictions | |
| Prescriber Restrictions | Ophthalmologist |
| Coverage Duration | 8 weeks. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

OXTELLAR

Products Affected

- *oxcarbazepine oral tablet extended release 24 hr 150 mg, 300 mg, 600 mg*
- OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG, 600 MG

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to oxcarbazepine immediate release. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PAH

Products Affected

- *ambrisentan*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Cardiologist, Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to the formulary alternative: sildenafil or tadalafil. Approve if in combination with tadalafil for treatment naive PAH patients with WHO FC II and III. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PARATHYROID HORMONE ANALOGS

Products Affected

- *teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)*
- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Bone mineral density (BMD) T score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) OR BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and a history of fractures. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to one of the formulary alternatives: alendronic acid or risedronate. Medical justification required for treatment duration beyond 24 months. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PDE5 INHIBITORS

Products Affected

- *alyq*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- TADLIQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with nitrates or PDE5 inhibitors. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Cardiologist, Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PEGFILGRASTIM

Products Affected

- FULPHILA
- UDENYCA
- UDENYCA AUTOINJECTOR
- UDENYCA ONBODY
- ZIEXTENZO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hematologist, Infectious Disease specialist, Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to formulary alternative: Nivestym and Zarxio. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PHENOBARBITAL

Products Affected

- *phenobarbital*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Anticonvulsant: Failure or clinically significant adverse effects to two of the formulary alternatives: carbamazepine, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, or zonisamide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PIMECROLIMUS

Products Affected

- *pimecrolimus*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to one of the topical formulary alternatives: clobetasol, betamethasone, fluocinolone or fluocinonide and failure or clinically significant adverse effects to the formulary alternative: tacrolimus ointment. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

POSACONAZOLE

Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole oral*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to one of the formulary alternatives: fluconazole, itraconazole, or voriconazole. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PRADAXA PELLETT

Products Affected

- PRADAXA ORAL PELLETS IN PACKET

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Pediatric patients aged 3 months to less than 12 years of age. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PREMARIN TABLETS

Products Affected

- PREMARIN ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to the formulary alternative: estradiol cream. Other indication(s): Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol transdermal patch or estradiol tablet. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PREMPRO TABLETS

Products Affected

- PREMPRO

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to the formulary alternative: estradiol cream. Other indication(s): Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol transdermal patch or estradiol tablet. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PREVYMIS

Products Affected

- PREVYMIS ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist, Oncologist, Transplant specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PROCRIT

Products Affected

- PROCRIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Uncontrolled hypertension. |
| Required Medical Information | For anemia due to chronic kidney disease: Hemoglobin (Hgb) is less than 10g/dL and documentation of transferrin saturation greater than or equal to 20% and ferritin greater than or equal to 100ng/mL. For anemia due to chemotherapy: Hemoglobin (Hgb) is less than 10g/dL. For surgical FDA indications: Hemoglobin (Hgb) is 10g/dL-13g/dL and patient is not a candidate for autologous blood donation and significant blood loss is anticipated from elective, non cardiac, or nonvascular surgery. Zidovudine induced: Hemoglobin (Hgb) is less than 11g/dL. Myelodysplastic syndrome: Hemoglobin (Hgb) is less than 11g/dL and erythropoietin is less than or equal to 500 mU/mL. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PROLASTIN C

Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Clinical evidence of emphysema |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year |
| Other Criteria | Pre-treatment serum levels of alpha-1 antitrypsin (AAT) that is less than 11 micromol/L (80 mg/dl by radial immunodiffusion or 50 mg/dl by nephelometry) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PROLIA

Products Affected

- PROLIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of bone mineral density (BMD) T-score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) OR BMD T-score between -2.5 and -3.5 (greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and a history of fractures. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PROMACTA

Products Affected

- PROMACTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of platelet count. Thrombocytopenia in hepatitis C infection: Documentation of concurrent or planned interferon-based treatment of chronic hepatitis C. |
| Age Restrictions | |
| Prescriber Restrictions | Gastroenterologist, Hematologist, Hepatologist, Infectious Disease specialist, Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Chronic immune (idiopathic) thrombocytopenia: Failure or clinically significant adverse effects to one of the formulary alternatives: dexamethasone, methylprednisolone, prednisolone or prednisone. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PROMETHAZINE

Products Affected

- *promethazine oral*
- *promethazine rectal suppository 12.5 mg, 25 mg*
- *promethegan rectal suppository 25 mg, 50 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Allergy: Failure or clinically significant adverse effects to one of the formulary alternatives: cetirizine and levocetirizine. Nausea and vomiting: Failure or clinically significant adverse effects to two of the formulary alternatives: chlorpromazine, granisetron, ondansetron, or prochlorperazine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PROTRIPTYLINE

Products Affected

- *protriptyline*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

PYRIMETHAMINE

Products Affected

- *pyrimethamine*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | Anemia due to folate deficiency |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hematologist, HIV specialist, Infectious Disease specialist, Oncologist, Transplant specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Primary prophylaxis of toxoplasmic encephalitis: Failure or clinically significant adverse effects to the formulary alternative: trimethoprim/sulfamethoxazole. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

QUININE

Products Affected

- *quinine sulfate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Prevention or treatment of nocturnal leg cramps. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 10 days. |
| Other Criteria | Failure or clinically significant adverse effects to one of the formulary alternatives: chloroquine or hydroxychloroquine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

REPATHA

Products Affected

- REPATHA PUSHTRONEX
- REPATHA SURECLICK
- REPATHA SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Primary hyperlipidemia: Documentation of current LDL levels above 100mg/dL while taking maximally tolerated statin therapy and ezetimibe therapy, unless intolerant or contraindicated to statin or ezetimibe therapy. Secondary prevention of ASCVD: Documentation of at least one high risk feature: recent ACS (within the past 12 months), history of MI, history of ischemic stroke, or symptomatic peripheral arterial disease (history of claudication with ABI greater than 0.85, or previous revascularization or amputation). Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH): Documentation to confirm diagnosis by genetic testing or by clinical criteria (such as Simon Broome or the Dutch Lipid Clinic Network criteria, or history of untreated LDL-C greater than 180 mg/dL together with xanthoma or cornealis), or evidence of Familial Hypercholesterolemia in first or second-degree relatives. |
| Age Restrictions | |
| Prescriber Restrictions | Cardiologist, Endocrinologist, Lipid specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RETACRIT

Products Affected

- RETACRIT INJECTION SOLUTION 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 10,000 UNIT/ML, 2,000 UNIT/ML, 40,000 UNIT/ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Uncontrolled hypertension. |
| Required Medical Information | For anemia due to chronic kidney disease: Hemoglobin (Hgb) is less than 10g/dL and documentation of transferrin saturation greater than or equal to 20% and ferritin greater than or equal to 100ng/mL. For anemia due to chemotherapy: Hemoglobin (Hgb) is less than 10g/dL. For surgical FDA indications: Hemoglobin (Hgb) is 10g/dL-13g/dL and patient is not a candidate for autologous blood donation and significant blood loss is anticipated from elective, non cardiac, or nonvascular surgery. Zidovudine induced: Hemoglobin (Hgb) is less than 11g/dL. Myelodysplastic syndrome: Hemoglobin (Hgb) is less than 11g/dL and erythropoietin is less than or equal to 500 mU/mL. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

REXULTI

Products Affected

- REXULTI ORAL TABLET

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Schizophrenia: Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, risperidone, quetiapine, ziprasidone or aripiprazole. Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, or venlafaxine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

REZUROCK

Products Affected

- REZUROCK

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RINVOQ

Products Affected

- RINVOQ LQ
- RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Rheumatologist, dermatologist, gastroenterologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | <p>Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.</p> <p>Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Non-radiographic Axial Spondyloarthritis: Failure or clinically significant adverse effects to a non-steroidal anti-inflammatory drug (NSAID) or has an intolerance or contraindication to NSAID. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine.</p> <p>Initial Atopic Dermatitis: 1) Atopic Dermatitis covering at least 10 percent of body surface area or Atopic Dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas, 2) intractable pruritus or cracking/oozing/bleeding of affected skin, 3) trial of or contraindication to one topical (corticosteroid or calcineurin inhibitor), and 4) no concurrent use with other systemic biologic for Atopic Dermatitis. Renewal: Atopic Dermatitis: 1) improvement while on therapy, and 2) no concurrent use with other systemic biologic for Atopic Dermatitis.</p> |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|----------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |

RISPERDAL CONSTA

Products Affected

- RISPERDAL CONSTA
- *risperidone microspheres*
- UZEDY

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to the formulary alternative: oral risperidone. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

RUFINAMIDE

Products Affected

- *rufinamide oral suspension*
- *rufinamide oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Failure or clinically significant adverse effects to one of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, clobazam or zonisamide. For Rufinamide suspension: Failure or clinically significant adverse effects to one of the formulary alternatives: Rufinamide tablet. |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SAPROPTERIN

Products Affected

- *sapropterin*

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SECUADO

Products Affected

- SECUADO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SIGNIFOR

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SIRTURO

Products Affected

- SIRTURO ORAL TABLET 100 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SKYRIZI

Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals. |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, gastroenterologist, rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Plaque psoriasis: Failure or clinically significant adverse effects to one of the following: acitretin, cyclosporine, methotrexate or phototherapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SOFOSBUVIR-VELPATASVIR

Products Affected

- *sofosbuvir-velpatasvir*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines. |
| Age Restrictions | |
| Prescriber Restrictions | Gastroenterologist, Hepatologist, Infectious Disease specialist |
| Coverage Duration | Duration will be applied consistent with current AASLD/IDSA guidance. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SOMAVERT

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Endocrinologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to the formulary alternative: octreotide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SPRITAM

Products Affected

- SPRITAM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to the formulary alternative: levetiracetam oral solution. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

STELARA

Products Affected

- STELARA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals. |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Gastroenterologist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SYMPAZAN

Products Affected

- SYMPAZAN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of difficulty or inability to swallow. |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

SYNAREL

Products Affected

- SYNAREL

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TACROLIMUS OINTMENT

Products Affected

- *tacrolimus topical*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the topical formulary alternatives: clobetasol, betamethasone, fluocinolone, or fluocinonide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TADALAFIL

Products Affected

- *tadalafil oral tablet 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Erectile Dysfunction without diagnosis of Benign Prostatic Hyperplasia (BPH). |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Benign Prostatic Hyperplasia: 1) trial of one alpha blocker (e.g., doxazosin, terazosin, tamsulosin, alfuzosin), and 2) trial of one 5-alpha-reductase inhibitor (e.g., finasteride, dutasteride). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TAKHZYRO

Products Affected

- TAKHZYRO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of hereditary angioedema (HAE), must be confirmed by blood testing. |
| Age Restrictions | |
| Prescriber Restrictions | Allergist, Immunologist, Hematologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TALTZ

Products Affected

- TALTZ AUTOINJECTOR
- TALTZ SYRINGE

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals. |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TARGRETIN

Products Affected

- *bexarotene*
- TARGRETIN TOPICAL

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TAVNEOS

Products Affected

- TAVNEOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | 1) Diagnosis of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) variant of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, 2) positive test for either anti-PR3 or anti-MPO, 3) at least 1 major item, 3 non-major items, or 2 renal items of proteinuria and hematuria on the Birmingham Vasculitis Activity Score (BVAS), 4) eGFR greater than or equal to 15 mL/min/1.72 m ² , 5) currently receiving standard therapy with cyclophosphamide or rituximab |
| Age Restrictions | |
| Prescriber Restrictions | Rheumatologist, Nephrologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TAZORAC

Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*
- TAZORAC TOPICAL CREAM 0.05 %
- TAZORAC TOPICAL GEL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Plaque psoriasis: Failure or clinically significant adverse effects to one of the topical formulary alternatives: calcipotriene, clobetasol or fluocinonide. Acne vulgaris: Failure or clinically significant adverse effects to two of the formulary alternatives: benzoyl peroxide/clindamycin topical, benzoyl peroxide/erythromycin topical, clindamycin topical, doxycycline oral, erythromycin topical, minocycline oral, tetracycline oral or tretinoin topical. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TECFIDERA

Products Affected

- *dimethyl fumarate*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TESTOSTERONE

Products Affected

- *methyltestosterone oral capsule*
- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*
- *testosterone transdermal solution in metered pump w/app*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documented pretreatment serum testosterone levels less than the laboratory's lower reference limit within the recent 3 months. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TESTOSTERONE PUMP

Products Affected

- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documented pretreatment serum testosterone levels less than the laboratory's lower reference limit within the recent 3 months. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: testosterone cypionate, testosterone enanthate or testosterone transdermal gel or solution. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TETRABENAZINE

Products Affected

- *tetrabenazine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with an MAOI. Untreated or inadequately-treated depression, or current suicidality. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TIGECYCLINE

Products Affected

- *tigecycline*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TOBI PODHALER

Products Affected

- TOBI PODHALER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist, Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TOBRAMYCIN SOLUTION

Products Affected

- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Infectious Disease specialist, Pulmonologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TOLCAPONE

Products Affected

- *tolcapone*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of concurrent use with levodopa and carbidopa. |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: amantadine, bromocriptine, carbidopa/levodopa, entacapone, pramipexole, ropinirole, or selegiline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRELSTAR

Products Affected

- TRELSTAR INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRIENTINE

Products Affected

- *trientine oral capsule 250 mg*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | Biliary cirrhosis, rheumatoid arthritis. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to the formulary alternative: penicillamine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRIHXYPHENIDYL

Products Affected

- *trihexyphenidyl*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Narrow angle glaucoma. |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Parkinsonism: Failure or clinically significant adverse effects to one of the formulary alternatives: amantadine, bromocriptine, carbidopa/levodopa, entacapone, pramipexole, ropinirole, or selegiline. Medication-induced movement disorder - extrapyramidal disease: Failure or clinically significant adverse effects to the formulary alternative: amantadine. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRIMIPRAMINE

Products Affected

- *trimipramine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply. |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

TRINTELLIX

Products Affected

- TRINTELLIX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

UBRELVY

Products Affected

- UBRELVY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Medical justification specifying that TWO formulary anti-migraine drugs from different classes have been tried and failed are contraindicated, or would not be medically appropriate. Classes include: (1) Analgesics- aspirin, naproxen, ibuprofen, diclofenac, celecoxib, indomethacin, nabumetone, and (2) Triptans- sumatriptan, rizatriptan/rizatriptan ODT |
| Age Restrictions | |
| Prescriber Restrictions | Neurologist, Pain Specialist, Headache Specialist |
| Coverage Duration | Until the end of calendar year |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VALCHLOR

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Dermatologist, Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VANCOMYCIN CAPSULE

Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | C diff diarrhea: Reauthorization: Documentation of C. Difficile positive stool |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VEMLIDY

Products Affected

- VEMLIDY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hepatologist, Gastroenterologist, Infectious Disease specialist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VEOZAH

Products Affected

- VEOZAH

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Menopausal vasomotor symptoms (VMS): initial: 1) experiences 7 or more hot flashes per day, and 2) trial of or contraindication to hormonal therapy (e.g., estradiol transdermal patch, oral conjugated estrogens). Renewal: 1) continued need for VMS treatment (i.e., persistent hot flashes), and 2) reduction in VMS frequency or severity due to Veozah treatment. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VERQUVO

Products Affected

- VERQUVO

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Cardiologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VIBERZI

Products Affected

- VIBERZI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | History of gallbladder removal. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to the all of the formulary alternatives: dicyclomine and loperamide. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VIIBRYD

Products Affected

- VIIBRYD ORAL TABLET
- *vilazodone*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VORICONAZOLE

Products Affected

- *voriconazole intravenous*

| PA Criteria | Criteria Details |
|------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

VOWST

Products Affected

- VOWST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | 1) Diagnosis of greater than or equal to 2 recurrent Clostridioides Difficile Infection (CDI), 2) current episode of CDI must be controlled (less than 3 unformed/loose stools/day for 2 consecutive days) following 10 to 21 days of antibiotic therapy, 3) recent positive stool test for C. difficile, and 4) completion of antibiotic treatment |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

WEGOVY

Products Affected

- WEGOVY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concurrent use with DPP4 inhibitors, history of Type 1 or Type 2 Diabetes Mellitus, and/or history of NYHA Class IV Heart Failure. Use of weight loss only. |
| Required Medical Information | BMI greater than or equal to 27 kg/m ² . Documentation of one of the following: prior MI, prior stroke, symptomatic PAD (evidenced by intermittent claudication with ABI less than 0.85 at rest and/or peripheral arterial revascularization procedure and/or amputation due to ASCVD). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Reauthorization only: Documentation of positive response to medication therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

XATMEP

Products Affected

- XATMEP

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Oncologist, Pediatrician, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Subject to Part B vs Part D determination. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

XDEMVY

Products Affected

- XDEMVY

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

XELJANZ

Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET
- XELJANZ XR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Gastroenterologist, Rheumatologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ulcerative colitis: Failure or clinically significant adverse effects to formulary alternative: Humira. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

XGEVA

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|---------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

XIFAXAN

Products Affected

- XIFAXAN

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Hepatic encephalopathy: Failure or clinically significant adverse effects to the formulary alternative: lactulose. Irritable bowel syndrome with diarrhea: Failure or clinically significant adverse effects to all of the formulary alternative: loperamide. Traveler's diarrhea: Failure or clinically significant adverse effects to one of the formulary alternatives: ciprofloxacin or levofloxacin. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

XOLAIR

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Asthma (Initial): Forced expiratory volume in one second or peak expiratory flow less than or equal to 80% of predicted level, or measures of asthma control indicate uncontrolled asthma (eg, Asthma Control Test [ACT] score 19 or less). Baseline (pre-Xolair treatment) serum total IgE level greater than or equal to 30 IU/mL. Positive skin test or in vitro reactivity to a perennial aeroallergen. |
| Age Restrictions | |
| Prescriber Restrictions | Allergist, Dermatologist, Immunologist, Pulmonologist, Otolaryngologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

XYREM

Products Affected

- *sodium oxybate*
- XYREM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Daytime excessive sleepiness in patients with narcolepsy: Failure or clinically significant adverse effects to two of the formulary alternatives: dextroamphetamine, methylphenidate, and modafinil. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ZARXIO

Products Affected

- ZARXIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | Hematologist, Infectious Disease specialist, Oncologist |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ZEPATIER

Products Affected

- ZEPATIER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines. For genotype 1a: Documentation for NS5A polymorphism testing. |
| Age Restrictions | |
| Prescriber Restrictions | Gastroenterologist, Hepatologist, Infectious Disease specialist |
| Coverage Duration | Duration will be applied consistent with current AASLD/IDSA guidance. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

ZYPREXA RELPREVV

Products Affected

- ZYPREXA RELPREVV
INTRAMUSCULAR SUSPENSION FOR
RECONSTITUTION 210 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documented history of receiving oral olanzapine without any clinically significant side effects. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Until the end of calendar year. |
| Other Criteria | Failure or clinically significant adverse effects to two of the formulary alternatives: Invega Sustenna, Invega Trinza or Risperdal Consta. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

INDEX

1

1ST TIER UNIFINE PENTP 5MM 31G. 74,
83, 84

1ST TIER UNIFINE PNTIP 4MM 32G.. 74,
83, 84

1ST TIER UNIFINE PNTIP 6MM 31G.. 74,
83, 84

1ST TIER UNIFINE PNTIP 8MM 31G
STRL,SINGLE-USE,SHRT 74, 83, 84

1ST TIER UNIFINE PNTP 29GX1/2 74, 83,
84

1ST TIER UNIFINE PNTP 31GX3/16 ... 74,
83, 84

1ST TIER UNIFINE PNTP 32GX5/32 ... 74,
83, 84

A

ABELCET..... 1

ABILIFY ASIMTUFII
INTRAMUSCULAR
SUSPENSION,EXTENDED REL
SYRING 720 MG/2.4 ML, 960 MG/3.2
ML..... 2

ABILIFY MAINTENA
INTRAMUSCULAR
SUSPENSION,EXTENDED REL
RECON 300 MG, 400 MG 2

ABILIFY MAINTENA
INTRAMUSCULAR
SUSPENSION,EXTENDED REL
SYRING..... 2

abiraterone oral tablet 250 mg, 500 mg ... 15,
17

ABOUTTIME PEN NEEDLE 30G X 8MM
..... 74, 83, 84

ABOUTTIME PEN NEEDLE 31G X 5MM
..... 74, 83, 84

ABOUTTIME PEN NEEDLE 31G X 8MM
..... 74, 83, 84

ABOUTTIME PEN NEEDLE 32G X 4MM
..... 74, 83, 84

acitretin 3

ACTIMMUNE..... 4

adefovir 5

ADVOCATE INS 0.3 ML 30GX5/16 74, 83,
84

ADVOCATE INS 0.3 ML 31GX5/16 74, 83,
84

ADVOCATE INS 0.5 ML 30GX5/16 74, 83,
84

ADVOCATE INS 0.5 ML 31GX5/16 74, 83,
84

ADVOCATE INS 1 ML 31GX5/16 .. 74, 83,
84

ADVOCATE INS SYR 0.3 ML 29GX1/2
..... 74, 83, 84

ADVOCATE INS SYR 0.5 ML 29GX1/2
..... 74, 83, 84

ADVOCATE INS SYR 1 ML 29GX1/2 . 74,
83, 84

ADVOCATE INS SYR 1 ML 30GX5/16 74,
83, 84

ADVOCATE PEN NDL 12.7MM 29G... 74,
83, 84

ADVOCATE PEN NEEDLE 32G 4MM 74,
83, 84

ADVOCATE PEN NEEDLE 4MM 33G 74,
83, 84

ADVOCATE PEN NEEDLES 5MM 31G
..... 74, 83, 84

ADVOCATE PEN NEEDLES 8MM 31G
..... 74, 83, 84

AFINITOR DISPERZ ORAL TABLET
FOR SUSPENSION 2 MG 15, 17

AIMOVIG AUTOINJECTOR..... 7

AKEEGA 15, 17

ALCOHOL 70% SWABS 74, 83, 84

ALCOHOL PADS 74, 83, 84

ALCOHOL PREP SWABS 74, 83, 84

ALCOHOL WIPES 74, 83, 84

ALECENSA..... 15, 17

alose tron..... 8

ALUNBRIG..... 15, 17

alyq..... 127

AMBISOME..... 9

ambrisentan 125

amitriptyline..... 10

amitriptyline-chlordiazepoxide oral tablet
 12.5-5 mg, 25-10 mg..... 10
 amoxapine 11
 amphotericin b 12
 amphotericin b liposome..... 9
 aprepitant..... 18
 APTIOM ORAL TABLET 200 MG, 400
 MG, 600 MG, 800 MG 13
 AQ INSULIN SYR 1 ML 31G 8MM (RX)
 74, 83, 84
 AQINJECT PEN NEEDLE 31G 5MM ... 74,
 83, 84
 AQINJECT PEN NEEDLE 32G 4MM ... 74,
 83, 84
 ARCALYST 19
 ARIKAYCE..... 20
 armodafinil..... 22
 asenapine maleate 119
 ASSURE ID DUO PRO NDL 31G 5MM 74,
 83, 84
 ASSURE ID DUO-SHIELD 30GX3/16.. 74,
 83, 84
 ASSURE ID DUO-SHIELD 30GX5/16.. 74,
 83, 84
 ASSURE ID INSULIN SAFETY
 SYRINGE 1 ML 29 GAUGE X 1/2 74,
 83, 84
 ASSURE ID PEN NEEDLE 30GX3/16.. 74,
 83, 84
 ASSURE ID PEN NEEDLE 30GX5/16.. 74,
 83, 84
 ASSURE ID PEN NEEDLE 31GX3/16.. 74,
 83, 84
 ASSURE ID PRO PEN NDL 30G 5MM 74,
 83, 84
 ASSURE ID SYR 0.5 ML 29GX1/2 . 74, 83,
 84
 ASSURE ID SYR 0.5 ML 31GX15/64 ... 74,
 83, 84
 ASSURE ID SYR 1 ML 31GX15/64 74, 83,
 84
 atovaquone 23
 AUBAGIO 24
 AUGTYRO ORAL CAPSULE 160 MG, 40
 MG 15, 17

AUSTEDO ORAL TABLET 12 MG, 6 MG,
 9 MG 25
 AUTOSHIELD DUO PEN NDL 30G 5MM
 74, 83, 84
 AUVELITY 26
 AYVAKIT ORAL TABLET 100 MG, 200
 MG, 25 MG, 300 MG, 50 MG..... 15, 17
B
 BALVERSA ORAL TABLET 3 MG, 4
 MG, 5 MG..... 15, 17
 BD AUTOSHIELD DUO NDL 5MMX30G
 74, 83, 84
 BD ECLIPSE 30GX1/2 74, 83, 84
 BD ECLIPSE NEEDLE 30GX1/2 74, 83, 84
 BD INS SYR 0.3 ML 8MMX31G(1/2)... 74,
 83, 84
 BD INS SYR UF 0.3 ML 12.7MMX30G 74,
 83, 84
 BD INS SYRINGE 1/2 ML 6MMX31G
 (ONLY FOR 500 UNIT/ML INSULIN)
 74, 83, 84
 BD INS SYRN UF 1 ML 12.7MMX30G
 NOT FOR RETAIL SALE 74, 83, 84
 BD INSULIN SYR 1 ML 25GX1 74, 83, 84
 BD INSULIN SYR 1 ML 25GX5/8 .. 74, 83,
 84
 BD INSULIN SYR 1 ML 26GX1/2 .. 74, 83,
 84
 BD INSULIN SYR 1 ML 27GX12.7MM 74,
 83, 84
 BD INSULIN SYR 1 ML 27GX5/8 .. 74, 83,
 84
 BD INSULIN SYR UF 1 ML 8MMX31G
 74, 83, 84
 BD INSULIN SYRINGE SLIP TIP .. 74, 83,
 84
 BD LUER-LOK SYRINGE 1 ML 74, 83, 84
 BD NANO 2 GEN PEN NDL 32G 4MM 74,
 83, 84
 BD SAFETGLD INS 0.3 ML 29G 13MM
 74, 83, 84
 BD SAFETGLD INS 0.5 ML 13MMX29G
 74, 83, 84
 BD SAFETYGLD INS 0.3 ML 31G 8MM
 74, 83, 84

| | | | |
|---|------------|--|------------|
| BD SAFETYGLD INS 0.5 ML 30G 8MM | 74, 83, 84 | CAREFINE PEN NEEDLE 12.7MM 29G | 75, 83, 84 |
| BD SAFETYGLD INS 1 ML 29G 13MM | 74, 83, 84 | CAREFINE PEN NEEDLE 4MM 32G ... | 75, 83, 84 |
| BD SAFETYGLID INS 1 ML 6MMX31G | 74, 83, 84 | CAREFINE PEN NEEDLE 5MM 32G ... | 75, 83, 84 |
| BD SAFETYGLIDE SYRINGE 27GX5/8 | 74, 83, 84 | CAREFINE PEN NEEDLE 6MM 31G ... | 75, 83, 84 |
| BD SAFTYGLD INS 0.3 ML 6MMX31G | 75, 83, 84 | CAREFINE PEN NEEDLE 8MM 30G ... | 75, 83, 84 |
| BD SAFTYGLD INS 0.5 ML 29G 13MM | 75, 83, 84 | CAREFINE PEN NEEDLES 6MM 32G. | 75, 83, 84 |
| BD SAFTYGLD INS 0.5 ML 6MMX31G | 75, 83, 84 | CAREFINE PEN NEEDLES 8MM 31G. | 75, 83, 84 |
| BD SINGLE USE SWAB..... | 75, 83, 84 | CARETOUCH ALCOHOL 70% PREP PAD..... | 75, 83, 84 |
| BD UF MICRO PEN NEEDLE 6MMX32G | 75, 83, 84 | CARETOUCH PEN NEEDLE 29G 12MM | 75, 83, 84 |
| BD UF MINI PEN NEEDLE 5MMX31G75, 83, 84 | | CARETOUCH PEN NEEDLE 31GX1/4 75, 83, 84 | |
| BD UF NANO PEN NEEDLE 4MMX32G | 75, 83, 84 | CARETOUCH PEN NEEDLE 31GX3/16 | 75, 83, 84 |
| BD UF ORIG PEN NDL 12.7MMX29G | 75, 83, 84 | CARETOUCH PEN NEEDLE 31GX5/16 | 75, 83, 84 |
| BD UF SHORT PEN NEEDLE 8MMX31G | 75, 83, 84 | CARETOUCH PEN NEEDLE 32GX3/16 | 75, 83, 84 |
| BD VEO INS 0.3 ML 6MMX31G (1/2).. | 75, 83, 84 | CARETOUCH PEN NEEDLE 32GX5/32 | 75, 83, 84 |
| BD VEO INS SYRING 1 ML 6MMX31G | 75, 83, 84 | CARETOUCH PEN NEEDLE 32GX5/32 | 75, 83, 84 |
| BD VEO INS SYRN 0.3 ML 6MMX31G75, 83, 84 | | CARETOUCH SYR 0.3 ML 31GX5/16 . | 75, 83, 84 |
| BD VEO INS SYRN 0.5 ML 6MMX31G75, 83, 84 | | CARETOUCH SYR 0.5 ML 30GX5/16 . | 75, 83, 84 |
| BESREMI | 15, 17 | CARETOUCH SYR 0.5 ML 31GX5/16 . | 75, 83, 84 |
| bexarotene | 167 | CARETOUCH SYR 1 ML 28GX5/16 | 75, 83, 84 |
| BORDERED GAUZE 2 | 75, 83, 84 | CARETOUCH SYR 1 ML 29GX5/16 | 75, 83, 84 |
| BOSULIF | 15, 17 | CARETOUCH SYR 1 ML 30GX5/16 | 75, 83, 84 |
| BRAFTOVL..... | 15, 17 | CARETOUCH SYR 1 ML 31GX5/16 | 75, 83, 84 |
| BRONCHITOL..... | 27 | casprofungin | 28 |
| BRUKINSA | 15, 17 | CIMZIA POWDER FOR RECONST | 29 |
| C | | CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 29 |
| CABOMETYX | 15, 17 | | |
| CALQUENCE (ACALABRUTINIB MAL) | 15, 17 | | |
| CAPLYTA | 119 | | |
| CAPRELSA | 15, 17 | | |

CLICKFINE 31G X 5/16..... 75, 83, 84
 CLICKFINE PEN NEEDLE 32GX5/32.. 75, 83, 84
 CLICKFINE UNIVERSAL 31G X 1/4 ... 75, 83, 84
 clobazam oral suspension 14
 clobazam oral tablet 14
 clomipramine 30
 COBENFY 119
 COBENFY STARTER PACK 119
 COMETRIQ..... 15, 17
 COMFORT EZ 0.3 ML 31G 15/64 ... 75, 83, 84
 COMFORT EZ 0.5 ML 31G 15/64 ... 75, 83, 84
 COMFORT EZ INS 0.3 ML 30GX1/2 75, 83, 84
 COMFORT EZ INS 0.3 ML 30GX5/16.. 75, 83, 84
 COMFORT EZ INS 1 ML 31G 15/64 75, 83, 84
 COMFORT EZ INS 1 ML 31GX5/16 75, 83, 84
 COMFORT EZ INSULIN SYR 0.3 ML.. 75, 83, 84
 COMFORT EZ INSULIN SYR 0.5 ML.. 75, 83, 84
 COMFORT EZ PEN NEEDLE 12MM 29G 75, 83, 84
 COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO..... 75, 83, 84
 COMFORT EZ PEN NEEDLES 4MM 33G 75, 83, 84
 COMFORT EZ PEN NEEDLES 5MM 31G MINI 75, 83, 84
 COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI..... 75, 83, 84
 COMFORT EZ PEN NEEDLES 5MM 33G 75, 83, 84
 COMFORT EZ PEN NEEDLES 6MM 31G 75, 83, 84
 COMFORT EZ PEN NEEDLES 6MM 32G 75, 83, 84
 COMFORT EZ PEN NEEDLES 6MM 33G 75, 83, 84

COMFORT EZ PEN NEEDLES 8MM 31G SHORT 75, 83, 84
 COMFORT EZ PEN NEEDLES 8MM 32G 75, 83, 84
 COMFORT EZ PEN NEEDLES 8MM 33G 75, 83, 84
 COMFORT EZ PRO PEN NDL 30G 8MM 75, 83, 84
 COMFORT EZ PRO PEN NDL 31G 4MM 75, 83, 84
 COMFORT EZ PRO PEN NDL 31G 5MM 75, 83, 84
 COMFORT EZ SYR 0.3 ML 29GX1/2... 75, 83, 84
 COMFORT EZ SYR 0.5 ML 28GX1/2... 75, 83, 84
 COMFORT EZ SYR 0.5 ML 29GX1/2... 75, 83, 84
 COMFORT EZ SYR 0.5 ML 30GX1/2... 75, 83, 84
 COMFORT EZ SYR 1 ML 28GX1/2 76, 83, 84
 COMFORT EZ SYR 1 ML 29GX1/2 76, 83, 84
 COMFORT EZ SYR 1 ML 30GX1/2 76, 83, 84
 COMFORT EZ SYR 1 ML 30GX5/16.... 76, 83, 84
 COMFORT POINT PEN NDL 31GX1/3 76, 83, 84
 COMFORT POINT PEN NDL 31GX1/6 76, 83, 84
 COMFORT TOUCH PEN NDL 31G 4MM 76, 83, 84
 COMFORT TOUCH PEN NDL 31G 5MM 76, 83, 84
 COMFORT TOUCH PEN NDL 31G 6MM 76, 83, 84
 COMFORT TOUCH PEN NDL 31G 8MM 76, 83, 84
 COMFORT TOUCH PEN NDL 32G 4MM 76, 83, 84
 COMFORT TOUCH PEN NDL 32G 5MM 76, 83, 84
 COMFORT TOUCH PEN NDL 32G 6MM 76, 83, 84

| | | | |
|--|------------|---------------------------------------|------------|
| COMFORT TOUCH PEN NDL 32G 8MM | 76, 83, 84 | doxepin oral concentrate | 42 |
| COMFORT TOUCH PEN NDL 33G 4MM | 76, 83, 84 | DRIZALMA SPRINKLE | 43 |
| COMFORT TOUCH PEN NDL 33G 6MM | 76, 83, 84 | dronabinol | 44 |
| COMFORT TOUCH PEN NDL 33GX5MM | 76, 83, 84 | DROPLET 0.5 ML 29GX12.5MM(1/2).. | 76, 83, 84 |
| COPIKTRA..... | 15, 17 | DROPLET 0.5 ML 30GX12.5MM(1/2).. | 76, 83, 84 |
| CORLANOR ORAL SOLUTION..... | 32 | DROPLET INS 0.3 ML 29GX12.5MM .. | 76, 83, 84 |
| CORLANOR ORAL TABLET | 32 | DROPLET INS 0.3 ML 30GX12.5MM .. | 76, 83, 84 |
| COSENTYX (2 SYRINGES)..... | 33 | DROPLET INS 0.5 ML 30GX6MM(1/2) | 76, 83, 84 |
| COSENTYX PEN (2 PENS) | 33 | DROPLET INS 0.5 ML 30GX8MM(1/2) | 76, 83, 84 |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML..... | 33 | DROPLET INS 0.5 ML 31GX6MM(1/2) | 76, 83, 84 |
| COSENTYX UNOREADY PEN | 33 | DROPLET INS 0.5 ML 31GX8MM(1/2) | 76, 83, 84 |
| COTELLIC | 15, 17 | DROPLET INS SYR 0.3 ML 30GX6MM | 76, 83, 84 |
| CURAD GAUZE PADS 2..... | 76, 83, 84 | DROPLET INS SYR 0.3 ML 30GX8MM | 76, 83, 84 |
| CURITY ALCOHOL PREPS 2 PLY,MEDIUM | 76, 83, 84 | DROPLET INS SYR 0.3 ML 31GX6MM | 76, 83, 84 |
| CURITY GAUZE SPONGES (12 PLY)-200/BAG | 76, 83, 84 | DROPLET INS SYR 0.3 ML 31GX8MM | 76, 83, 84 |
| CURITY GUAZE PADS 1'S(12 PLY).... | 76, 83, 84 | DROPLET INS SYR 1 ML 29GX12.5MM | 76, 83, 84 |
| cyclobenzaprine oral tablet 10 mg, 5 mg.. | 34 | DROPLET INS SYR 1 ML 30GX12.5MM | 76, 83, 84 |
| D | | DROPLET INS SYR 1 ML 30GX6MM . | 76, 83, 84 |
| dalfampridine | 35 | DROPLET INS SYR 1 ML 30GX8MM . | 76, 83, 84 |
| DALIRESP | 36 | DROPLET INS SYR 1 ML 31GX6MM . | 76, 83, 84 |
| DANZITEN | 15, 17 | DROPLET INS SYR 1 ML 31GX8MM . | 76, 83, 84 |
| dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg | 15, 17 | DROPLET MICRON 34G X 9/64 | 76, 83, 84 |
| DAURISMO ORAL TABLET 100 MG, 25 MG | 15, 17 | DROPLET PEN NEEDLE 29G 10MM .. | 76, 83, 84 |
| deferasirox oral tablet, dispersible | 37 | DROPLET PEN NEEDLE 29G 12MM .. | 76, 83, 84 |
| DERMACEA 2 | 76, 83, 84 | DROPLET PEN NEEDLE 30G 8MM | 76, 83, 84 |
| DERMACEA GAUZE 2..... | 76, 83, 84 | | |
| DERMACEA NON-WOVEN 2 ... | 76, 83, 84 | | |
| desipramine | 38 | | |
| dexmethylphenidate oral tablet | 6 | | |
| DIACOMIT..... | 14 | | |
| diazepam intensol..... | 39 | | |
| diazepam oral solution 5 mg/5 ml (1 mg/ml) | 39 | | |
| dimethyl fumarate | 40, 170 | | |
| disopyramide phosphate oral capsule | 41 | | |
| doxepin oral capsule | 42 | | |

DROPLET PEN NEEDLE 31G 5MM 76,
 83, 84
 DROPLET PEN NEEDLE 31G 6MM 76,
 83, 84
 DROPLET PEN NEEDLE 31G 8MM 76,
 83, 84
 DROPLET PEN NEEDLE 32G 4MM 76,
 83, 84
 DROPLET PEN NEEDLE 32G 5MM 76,
 83, 84
 DROPLET PEN NEEDLE 32G 6MM 76,
 83, 84
 DROPLET PEN NEEDLE 32G 8MM 76,
 83, 84
 DROPSAFE ALCOHOL 70% PREP PADS
 76, 83, 84
 DROPSAFE INS SYR 0.3 ML 31G 6MM
 76, 83, 84
 DROPSAFE INS SYR 0.3 ML 31G 8MM
 76, 83, 84
 DROPSAFE INS SYR 0.5 ML 31G 6MM
 76, 83, 84
 DROPSAFE INS SYR 0.5 ML 31G 8MM
 76, 83, 84
 DROPSAFE INSUL SYR 1 ML 31G 6MM
 76, 83, 84
 DROPSAFE INSUL SYR 1 ML 31G 8MM
 76, 83, 84
 DROPSAFE INSULN 1 ML 29G 12.5MM
 76, 83, 84
 DROPSAFE PEN NEEDLE 31GX1/4 76,
 83, 84
 DROPSAFE PEN NEEDLE 31GX3/16 .. 76,
 83, 84
 DROPSAFE PEN NEEDLE 31GX5/16 .. 76,
 83, 84
 droxidopa 45
 DRUG MART ULTRA COMFORT SYR
 76, 83, 84
 DUAVEE 53
 DUPIXENT PEN 46, 47
 DUPIXENT SYRINGE SUBCUTANEOUS
 SYRINGE 200 MG/1.14 ML, 300 MG/2
 ML..... 46, 47

E
 EASY CMFT SFTY PEN NDL 31G 5MM
 76, 83, 84
 EASY CMFT SFTY PEN NDL 31G 6MM
 76, 83, 84
 EASY CMFT SFTY PEN NDL 32G 4MM
 77, 83, 84
 EASY COMFORT 0.3 ML 31G 1/2.. 77, 83,
 84
 EASY COMFORT 0.3 ML 31G 5/16 77, 83,
 84
 EASY COMFORT 0.3 ML SYRINGE ... 77,
 83, 84
 EASY COMFORT 0.5 ML 30GX1/2 77, 83,
 84
 EASY COMFORT 0.5 ML 31GX5/16.... 77,
 83, 84
 EASY COMFORT 0.5 ML 32GX5/16.... 77,
 83, 84
 EASY COMFORT 0.5 ML SYRINGE ... 77,
 83, 84
 EASY COMFORT 1 ML 31GX5/16. 77, 83,
 84
 EASY COMFORT 1 ML 32GX5/16. 77, 83,
 84
 EASY COMFORT ALCOHOL 70% PAD
 77, 83, 84
 EASY COMFORT INSULIN 1 ML SYR 77,
 83, 84
 EASY COMFORT PEN NDL 31GX1/4 . 77,
 83, 84
 EASY COMFORT PEN NDL 31GX3/16 77,
 83, 84
 EASY COMFORT PEN NDL 31GX5/16 77,
 83, 84
 EASY COMFORT PEN NDL 32GX5/32 77,
 83, 84
 EASY COMFORT PEN NDL 33G 4MM 77,
 83, 84
 EASY COMFORT PEN NDL 33G 5MM 77,
 83, 84
 EASY COMFORT PEN NDL 33G 6MM 77,
 83, 84
 EASY COMFORT SYR 1 ML 30GX1/2 77,
 83, 84

| | |
|---|--|
| EASY GLIDE INS 0.3 ML 31GX6MM.. 77, 83, 84 | EASY TOUCH INSULN 1 ML 31GX5/16 77, 83, 84 |
| EASY GLIDE INS 0.5 ML 31GX6MM.. 77, 83, 84 | EASY TOUCH LUER LOK INSUL 1 ML 77, 83, 84 |
| EASY GLIDE INS 1 ML 31GX6MM77, 83, 84 | EASY TOUCH PEN NEEDLE 29GX1/2 77, 83, 84 |
| EASY GLIDE PEN NEEDLE 4MM 33G77, 83, 84 | EASY TOUCH PEN NEEDLE 30GX5/16 77, 83, 84 |
| EASY TOUCH 0.3 ML SYR 30GX1/2... 77, 83, 84 | EASY TOUCH PEN NEEDLE 31GX1/4 77, 83, 84 |
| EASY TOUCH 0.5 ML SYR 27GX1/2... 77, 83, 84 | EASY TOUCH PEN NEEDLE 31GX3/16 77, 83, 84 |
| EASY TOUCH 0.5 ML SYR 29GX1/2... 77, 83, 84 | EASY TOUCH PEN NEEDLE 31GX5/16 77, 83, 84 |
| EASY TOUCH 0.5 ML SYR 30GX1/2... 77, 83, 84 | EASY TOUCH PEN NEEDLE 32GX1/4 77, 83, 84 |
| EASY TOUCH 0.5 ML SYR 30GX5/16. 77, 83, 84 | EASY TOUCH PEN NEEDLE 32GX3/16 77, 83, 84 |
| EASY TOUCH 1 ML SYR 27GX1/2 77, 83, 84 | EASY TOUCH PEN NEEDLE 32GX5/32 77, 83, 84 |
| EASY TOUCH 1 ML SYR 29GX1/2 77, 83, 84 | EASY TOUCH SAF PEN NDL 29G 5MM 77, 83, 84 |
| EASY TOUCH 1 ML SYR 30GX1/2 77, 83, 84 | EASY TOUCH SAF PEN NDL 29G 8MM 77, 83, 84 |
| EASY TOUCH ALCOHOL 70% PADS GAMMA-STERILIZED..... 77, 83, 84 | EASY TOUCH SAF PEN NDL 30G 5MM 77, 83, 84 |
| EASY TOUCH FLIPLOK 1 ML 27GX0.5 77, 83, 84 | EASY TOUCH SAF PEN NDL 30G 8MM 77, 83, 84 |
| EASY TOUCH INSULIN 1 ML 29GX1/2 77, 83, 84 | EASY TOUCH SYR 0.5 ML 28G 12.7MM 77, 83, 84 |
| EASY TOUCH INSULIN 1 ML 30GX1/2 77, 83, 84 | EASY TOUCH SYR 0.5 ML 29G 12.7MM 77, 83, 84 |
| EASY TOUCH INSULIN SYR 0.3 ML.. 77, 83, 84 | EASY TOUCH SYR 1 ML 27G 16MM.. 77, 83, 84 |
| EASY TOUCH INSULIN SYR 0.5 ML.. 77, 83, 84 | EASY TOUCH SYR 1 ML 28G 12.7MM 77, 83, 84 |
| EASY TOUCH INSULIN SYR 1 ML..... 77, 83, 84 | EASY TOUCH SYR 1 ML 29G 12.7MM 77, 83, 84 |
| EASY TOUCH INSULIN SYR 1 ML RETRACTABLE..... 77, 83, 84 | EASY TOUCH UNI-SLIP SYR 1 ML.... 77, 83, 84 |
| EASY TOUCH INSULN 1 ML 29GX1/277, 83, 84 | EASYTOUCH SAF PEN NDL 30G 6MM 77, 83, 84 |
| EASY TOUCH INSULN 1 ML 30GX1/277, 83, 84 | ELIGARD..... 48 |
| EASY TOUCH INSULN 1 ML 30GX5/16 77, 83, 84 | ELIGARD (3 MONTH)..... 48 |
| | ELIGARD (4 MONTH)..... 48 |
| | ELIGARD (6 MONTH)..... 48 |

| | |
|--|---|
| EMBRACE PEN NEEDLE 29G 12MM . 77, 83, 84 | FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)..... 55 |
| EMBRACE PEN NEEDLE 30G 5MM ... 77, 83, 84 | FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 55 |
| EMBRACE PEN NEEDLE 30G 8MM ... 77, 83, 84 | FIFTY50 INS 0.5 ML 31GX5/16. 77, 83, 84 |
| EMBRACE PEN NEEDLE 31G 5MM ... 77, 83, 84 | FIFTY50 PEN 31G X 3/16..... 77, 83, 84 |
| EMBRACE PEN NEEDLE 31G 6MM ... 77, 83, 84 | fingolimod..... 60 |
| EMBRACE PEN NEEDLE 31G 8MM ... 77, 83, 84 | FINTEPLA..... 14 |
| EMBRACE PEN NEEDLE 32G 4MM ... 77, 83, 84 | FIRMAGON KIT W DILUENT SYRINGE 57 |
| EMSAM..... 49 | FOTIVDA 15, 17 |
| ENBREL MINI..... 50 | FP INSULIN 1 ML SYRINGE..... 77, 83, 84 |
| ENBREL SUBCUTANEOUS SOLUTION 50 | FREESTYLE PREC 0.5 ML 30GX5/16 . 77, 83, 84 |
| ENBREL SUBCUTANEOUS SYRINGE 50 | FREESTYLE PREC 0.5 ML 31GX5/16 . 78, 83, 84 |
| ENBREL SURECLICK..... 50 | FREESTYLE PREC 1 ML 30GX5/16 78, 83, 84 |
| ENDARI 51 | FREESTYLE PREC 1 ML 31GX5/16 78, 83, 84 |
| EPIDIOLEX..... 13 | FRUZAQLA ORAL CAPSULE 1 MG, 5 MG 15, 17 |
| EQL INSULIN 0.3 ML SYRINGE SHORT NEEDLE 77, 83, 84 | FULPHILA 128 |
| EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE 77, 83, 84 | FYCOMPA ORAL SUSPENSION 13 |
| EQL INSULIN 1 ML SYRINGE SHORT NEEDLE 77, 83, 84 | FYCOMPA ORAL TABLET 13 |
| ERIVEDGE..... 15, 17 | G |
| ERLEADA ORAL TABLET 240 MG, 60 MG 15, 17 | GAUZE PAD TOPICAL BANDAGE 2 X 2 78, 83, 84 |
| erlotinib oral tablet 100 mg, 150 mg, 25 mg 15, 17 | GAVRETO 15, 17 |
| ESBRIET ORAL CAPSULE..... 52 | gefitinib 15, 17 |
| ESBRIET ORAL TABLET 267 MG, 801 MG 52 | GENOTROPIN 58 |
| estradiol oral..... 53 | GENOTROPIN MINIQUICK 58 |
| estradiol transdermal patch weekly..... 53 | GILENYA..... 60 |
| everolimus (antineoplastic) oral tablet 15, 17 | GILOTRIF 15, 17 |
| everolimus (antineoplastic) oral tablet for suspension 3 mg, 5 mg..... 15, 17 | glatiramer 61 |
| F | glatopa..... 62 |
| FANAPT 119 | GLEOSTINE..... 15, 17 |
| fentanyl citrate buccal lozenge on a handle 54 | glutamine (sickle cell)..... 51 |
| | glyburide 64 |
| | glyburide micronized 64 |
| | glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg..... 64 |
| | GNP ULT C 0.3 ML 29GX1/2 78, 83, 84 |
| | GNP ULTRA COMFORT 0.5 ML SYR . 78, 83, 84 |

GNP ULTRA COMFORT 1 ML SYRINGE
 78, 83, 84
 GNP ULTRA COMFORT 3/10 ML SYR 78,
 83, 84
 guanfacine oral tablet 65
 guanfacine oral tablet extended release 24 hr
 65
H
 HEALTHWISE INS 0.3 ML 30GX5/16 . 78,
 83, 84
 HEALTHWISE INS 0.3 ML 31GX5/16 . 78,
 83, 84
 HEALTHWISE INS 0.5 ML 30GX5/16 . 78,
 83, 84
 HEALTHWISE INS 0.5 ML 31GX5/16 . 78,
 83, 84
 HEALTHWISE INS 1 ML 30GX5/16 78,
 83, 84
 HEALTHWISE INS 1 ML 31GX5/16 78,
 83, 84
 HEALTHWISE PEN NEEDLE 31G 5MM
 78, 83, 84
 HEALTHWISE PEN NEEDLE 31G 8MM
 78, 83, 84
 HEALTHWISE PEN NEEDLE 32G 4MM
 78, 83, 84
 HEALTHY ACCENTS PENTIP 4MM 32G
 78, 83, 84
 HEALTHY ACCENTS PENTIP 5MM 31G
 78, 83, 84
 HEALTHY ACCENTS PENTIP 6MM 31G
 78, 83, 84
 HEALTHY ACCENTS PENTIP 8MM 31G
 78, 83, 84
 HEALTHY ACCENTS PENTIP 12MM 29G
 78, 83, 84
 HEB INCONTROL ALCOHOL 70% PADS
 78, 83, 84
 HUMIRA PEN 67
 HUMIRA SUBCUTANEOUS SYRINGE
 KIT 40 MG/0.8 ML 67
 HUMIRA(CF) 67
 HUMIRA(CF) PEDI CROHNS STARTER
 68
 HUMIRA(CF) PEN 67
 HUMIRA(CF) PEN CROHNS-UC-HS.... 67

HUMIRA(CF) PEN PEDIATRIC UC 68
 HUMIRA(CF) PEN PSOR-UV-ADOL HS
 67
I
 IBRANCE 15, 17
 icatibant 56
 ICLUSIG ORAL TABLET 10 MG, 15 MG,
 30 MG, 45 MG 15, 17
 IDHIFA 15, 17
 imatinib oral tablet 100 mg, 400 mg... 15, 17
 IMBRUVICA ORAL CAPSULE 140 MG,
 70 MG 15, 17
 IMBRUVICA ORAL SUSPENSION. 15, 17
 IMBRUVICA ORAL TABLET 140 MG,
 280 MG, 420 MG 15, 17
 imipramine hcl 69
 imipramine pamoate 69
 IMKELDI 15, 17
 IMPAVIDO 70
 INCONTROL PEN NEEDLE 12MM 29G
 78, 83, 84
 INCONTROL PEN NEEDLE 4MM 32G 78,
 83, 84
 INCONTROL PEN NEEDLE 5MM 31G 78,
 83, 84
 INCONTROL PEN NEEDLE 6MM 31G 78,
 83, 84
 INCONTROL PEN NEEDLE 8MM 31G 78,
 83, 84
 INCRELEX 71
 indomethacin oral capsule 72
 INGREZZA 73
 INGREZZA INITIATION PK(TARDIV) 73
 INGREZZA SPRINKLE 73
 INLYTA ORAL TABLET 1 MG, 5 MG. 15,
 17
 INQOVI 15, 17
 INREBIC 15, 17
 INSULIN SYR 0.3 ML 31GX1/4(1/2) 78,
 83, 84
 INSULIN SYRIN 0.5 ML 28GX1/2.. 78, 83,
 84
 INSULIN SYRIN 0.5 ML 29GX1/2.. 78, 83,
 84
 INSULIN SYRIN 0.5 ML 30GX1/2.. 78, 83,
 84

INSULIN SYRIN 0.5 ML 30GX5/16 78, 83,
 84
 INSULIN SYRING 0.5 ML 27G 1/2. 78, 83,
 84
 INSULIN SYRINGE 0.3 ML 78, 83, 84
 INSULIN SYRINGE 0.3 ML 31GX1/4 .. 78,
 83, 84
 INSULIN SYRINGE 0.5 ML 78, 83, 84
 INSULIN SYRINGE 0.5 ML 31GX1/4 .. 78,
 83, 84
 INSULIN SYRINGE 1 ML 78, 83, 84
 INSULIN SYRINGE 1 ML 27G 1/2 . 78, 83,
 84
 INSULIN SYRINGE 1 ML 27G 16MM . 78,
 83, 84
 INSULIN SYRINGE 1 ML 28GX1/2 78, 83,
 84
 INSULIN SYRINGE 1 ML 30GX1/2 78, 83,
 84
 INSULIN SYRINGE 1 ML 30GX5/16 ... 78,
 83, 84
 INSULIN SYRINGE 1 ML 31GX1/4 78, 83,
 84
 INSULIN SYRINGE-NEEDLE U-100
 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29
 GAUGE X 1/2..... 78, 83, 84
 INSUPEN 30G ULTRAFIN NEEDLE ... 78,
 83, 84
 INSUPEN 31G ULTRAFIN NEEDLE ... 78,
 83, 84
 INSUPEN 32G 6MM PEN NEEDLE 78, 83,
 84
 INSUPEN 32G 8MM PEN NEEDLE 78, 83,
 84
 INSUPEN PEN NEEDLE 29GX12MM.. 78,
 83, 84
 INSUPEN PEN NEEDLE 31GX3/16 78, 83,
 84
 INSUPEN PEN NEEDLE 32GX4MM.... 78,
 83, 84
 INSUPEN PEN NEEDLE 33GX4MM.... 78,
 83, 84
 INVEGA HAFYERA 86
 INVEGA SUSTENNA 87
 INVEGA TRINZA..... 88
 IRESSA..... 15, 17

ITOVEBI ORAL TABLET 3 MG, 9 MG 15,
 17
 itraconazole oral solution 89
 IV ANTISEPTIC WIPES 78, 83, 84
 ivabradine..... 32
 IWILFIN 15, 17
J
 JAKAFI..... 15, 17
 JAYPIRCA ORAL TABLET 100 MG, 50
 MG 15, 17
 JYLAMVO 90
K
 KALYDECO..... 91
 KENDALL ALCOHOL 70% PREP PAD78,
 83, 84
 KERENDIA 92
 KINERET 93
 KISQALI FEMARA CO-PACK 15, 17
 KISQALI ORAL TABLET 200 MG/DAY
 (200 MG X 1), 400 MG/DAY (200 MG X
 2), 600 MG/DAY (200 MG X 3).... 15, 17
 KORLYM 94
 KOSELUGO ORAL CAPSULE 10 MG, 25
 MG 15, 17
 KRAZATI..... 15, 17
L
 lapatinib..... 15, 17
 LATUDA ORAL TABLET 120 MG, 20
 MG, 40 MG, 60 MG, 80 MG..... 119
 LAZCLUZE ORAL TABLET 240 MG, 80
 MG 15, 17
 ledipasvir-sofosbuvir..... 95
 lenalidomide..... 15, 17
 LENVIMA ORAL CAPSULE 10 MG/DAY
 (10 MG X 1), 12 MG/DAY (4 MG X 3),
 14 MG/DAY(10 MG X 1-4 MG X 1), 18
 MG/DAY (10 MG X 1-4 MG X2), 20
 MG/DAY (10 MG X 2), 24 MG/DAY(10
 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY
 (4 MG X 2)..... 15, 17
 LEUKINE INJECTION RECON SOLN.. 96
 leuprolide (3 month) 97
 leuprolide subcutaneous kit..... 97
 levalbuterol hcl inhalation solution for
 nebulization 0.31 mg/3 ml, 0.63 mg/3 ml,
 1.25 mg/0.5 ml, 1.25 mg/3 ml..... 98

LIBERVANT 109
 lidocaine topical adhesive patch,medicated 5
 % 99
 LISCO SPONGES 100/BAG..... 78, 83, 84
 LITE TOUCH 31GX1/4 78, 83, 84
 LITE TOUCH INSULIN 0.5 ML SYR ... 78,
 83, 84
 LITE TOUCH INSULIN 1 ML SYR 78, 83,
 84
 LITE TOUCH INSULIN SYR 1 ML 78, 83,
 84
 LITE TOUCH PEN NEEDLE 29G ... 78, 83,
 84
 LITE TOUCH PEN NEEDLE 31G ... 78, 83,
 84
 LITETOUCH INS 0.3 ML 29GX1/2. 78, 83,
 84
 LITETOUCH INS 0.3 ML 30GX5/1678, 83,
 84
 LITETOUCH INS 0.3 ML 31GX5/1678, 83,
 84
 LITETOUCH INS 0.5 ML 31GX5/1678, 83,
 84
 LITETOUCH SYR 0.5 ML 28GX1/2 78, 83,
 84
 LITETOUCH SYR 0.5 ML 29GX1/2 79, 83,
 84
 LITETOUCH SYR 0.5 ML 30GX5/16 ... 79,
 83, 84
 LITETOUCH SYRIN 1 ML 28GX1/2 79,
 83, 84
 LITETOUCH SYRIN 1 ML 29GX1/2 79,
 83, 84
 LITETOUCH SYRIN 1 ML 30GX5/16 .. 79,
 83, 84
 LIVTENCITY 100
 LONSURF 15, 17
 LORBRENA ORAL TABLET 100 MG, 25
 MG 15, 17
 LUMAKRAS ORAL TABLET 120 MG,
 240 MG, 320 MG..... 16, 17
 LUPRON DEPOT..... 101
 LUPRON DEPOT (3 MONTH) 101
 LUPRON DEPOT (4 MONTH) 101
 LUPRON DEPOT (6 MONTH) 101

lurasidone oral tablet 120 mg, 20 mg, 40
 mg, 60 mg, 80 mg 119
 LYNPARZA 16, 17
 LYTGABI ORAL TABLET 12 MG/DAY
 (4 MG X 3), 16 MG/DAY (4 MG X 4),
 20 MG/DAY (4 MG X 5) 16, 17
M
 MAGELLAN INSUL SYRINGE 0.3 ML 79,
 83, 84
 MAGELLAN INSUL SYRINGE 0.5 ML 79,
 83, 84
 MAGELLAN INSULIN SYR 0.3 ML 79,
 83, 84
 MAGELLAN INSULIN SYR 0.5 ML 79,
 83, 84
 MAGELLAN INSULIN SYRINGE 1 ML
 79, 83, 84
 MATULANE 16, 17
 MAXICOMFORT II PEN NDL 31GX6MM
 79, 83, 84
 MAXICOMFORT INS 0.5 ML 27GX1/2 79,
 83, 84
 MAXI-COMFORT INS 0.5 ML 28G 79, 83,
 84
 MAXICOMFORT INS 1 ML 27GX1/2 .. 79,
 83, 84
 MAXI-COMFORT INS 1 ML 28GX1/2. 79,
 83, 84
 MAXICOMFORT PEN NDL 29G X 5MM
 79, 83, 84
 MAXICOMFORT PEN NDL 29G X 8MM
 79, 83, 84
 megestrol oral suspension 400 mg/10 ml (40
 mg/ml)..... 103
 megestrol oral tablet..... 103
 MEKINIST ORAL RECON SOLN ... 16, 17
 MEKINIST ORAL TABLET 0.5 MG, 2
 MG 16, 17
 MEKTOVI 16, 17
 meprobamate..... 104
 methocarbamol oral tablet 500 mg, 750 mg
 105
 methyl dopa-hydrochlorothiazide 106
 methylphenidate hcl oral capsule, er
 biphasic 30-70..... 6

methylphenidate hcl oral capsule,er biphasic
 50-50 6
 methylphenidate hcl oral solution..... 6
 methylphenidate hcl oral tablet..... 6
 methylphenidate hcl oral tablet extended
 release 6
 methyltestosterone oral capsule 171
 metyrosine..... 107
 MICRODOT PEN NEEDLE 31GX6MM 79,
 83, 84
 MICRODOT PEN NEEDLE 32GX4MM 79,
 83, 84
 MICRODOT PEN NEEDLE 33GX4MM 79,
 83, 84
 MICRODOT READYGARD NDL 31G
 5MM OUTER 79, 83, 84
 mifepristone oral tablet 300 mg 94
 MINI PEN NEEDLE 32G 4MM .. 79, 83, 84
 MINI PEN NEEDLE 32G 5MM .. 79, 83, 84
 MINI PEN NEEDLE 32G 6MM .. 79, 83, 84
 MINI PEN NEEDLE 32G 8MM .. 79, 83, 84
 MINI PEN NEEDLE 33G 4MM .. 79, 83, 84
 MINI PEN NEEDLE 33G 5MM .. 79, 83, 84
 MINI PEN NEEDLE 33G 6MM .. 79, 83, 84
 MINI ULTRA-THIN II PEN NDL 31G
 STERILE..... 79, 83, 84
 modafinil..... 108
 molindone oral tablet 10 mg, 25 mg, 5 mg 66
 MONOJECT 0.5 ML SYRN 28GX1/2.... 79,
 83, 84
 MONOJECT 1 ML SYRN 27X1/2.... 79, 83,
 84
 MONOJECT 1 ML SYRN 28GX1/2. 79, 83,
 84
 MONOJECT INSUL SYR U100 (OTC) . 79,
 83, 84
 MONOJECT INSUL SYR U100
 .5ML,29GX1/2..... 79, 83, 84
 MONOJECT INSUL SYR U100 0.5 ML
 CONVERTS TO 29G (OTC).... 79, 83, 84
 MONOJECT INSUL SYR U100 1 ML... 79,
 83, 84
 MONOJECT INSUL SYR U100 1 ML 3'S,
 29GX1/2..... 79, 83, 84
 MONOJECT INSUL SYR U100 1 ML W/O
 NEEDLE (OTC) 79, 83, 84

MONOJECT INSULIN SYR 0.3 ML 79, 83,
 84
 MONOJECT INSULIN SYR 0.3 ML (OTC)
 79, 83, 84
 MONOJECT INSULIN SYR 0.5 ML 79, 83,
 84
 MONOJECT INSULIN SYR 0.5 ML (OTC)
 79, 83, 84
 MONOJECT INSULIN SYR 1 ML 3'S
 (OTC)..... 79, 83, 84
 MONOJECT INSULIN SYR U-100 . 79, 83,
 84
 MONOJECT SYRINGE 0.3 ML.. 79, 83, 84
 MONOJECT SYRINGE 0.5 ML.. 79, 83, 84
 MONOJECT SYRINGE 1 ML..... 79, 83, 84
 MOTPOLY XR ORAL
 CAPSULE,EXTENDED RELEASE
 24HR 100 MG, 150 MG, 200 MG..... 14
 MOUNJARO 63
 MOVANTIK..... 31
N
 NAYZILAM 109
 NERLYNX 16, 17
 NEXAVAR..... 16, 17
 NINLARO..... 16, 17
 NIVESTYM INJECTION 110
 NOVOFINE 30 79, 83, 84
 NOVOFINE 32G NEEDLES 79, 83, 84
 NOVOFINE PLUS PEN NDL 32GX1/6. 79,
 83, 84
 NOVOTWIST NEEDLE 32G 5MM . 79, 83,
 84
 NOXAFIL ORAL SUSPENSION 131
 NUBEQA 16, 17
 NUCALA 111
 NUEDEXTA..... 112
 NUPLAZID..... 113
O
 octreotide acetate injection solution..... 114
 ODOMZO 16, 17
 OFEV 115
 OGSIVEO ORAL TABLET 100 MG, 150
 MG, 50 MG..... 16, 17
 OJEMDA ORAL SUSPENSION FOR
 RECONSTITUTION 16, 17
 OJEMDA ORAL TABLET 16, 17

| | |
|---|------------|
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG..... | 16, 17 |
| olanzapine intramuscular | 117 |
| olanzapine oral tablet,disintegrating | 116 |
| OMNITROPE | 118 |
| ONUREG | 16, 17 |
| OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG | 21 |
| ORENCIA CLICKJECT..... | 120 |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML..... | 120 |
| ORGOVYX..... | 16, 17 |
| ORKAMBI..... | 121 |
| ORSERDU ORAL TABLET 345 MG, 86 MG | 16, 17 |
| OTEZLA | 122 |
| OTEZLA STARTER | 122 |
| oxcarbazepine oral tablet extended release 24 hr 150 mg, 300 mg, 600 mg..... | 124 |
| OXERVATE | 123 |
| OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG, 600 MG..... | 124 |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 63 |
| P | |
| PANRETIN..... | 16, 17 |
| pazopanib | 16, 17 |
| PC UNIFINE PENTIPS 8MM NEEDLE SHORT | 79, 83, 84 |
| PEMAZYRE | 16, 17 |
| PEN NEEDLE 30G 5MM OUTER ... | 79, 83, 84 |
| PEN NEEDLE 30G 8MM INNER | 79, 83, 84 |
| PEN NEEDLE 30G X 5/16..... | 79, 83, 84 |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2..... | 79, 83, 84 |
| PEN NEEDLES 12MM 29G 29GX12MM,STRL..... | 79, 83, 84 |
| PEN NEEDLES 4MM 32G | 79, 83, 84 |
| PEN NEEDLES 6MM 31G 31GX6MM, STRL..... | 79, 83, 84 |
| PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC) | 79, 83, 84 |
| PENTIPS PEN NEEDLE 29G 1/2 | 79, 83, 84 |
| PENTIPS PEN NEEDLE 31G 1/4 | 79, 83, 84 |
| PENTIPS PEN NEEDLE 31GX3/16. | 79, 83, 84 |
| PENTIPS PEN NEEDLE 31GX5/16. | 79, 83, 84 |
| PENTIPS PEN NEEDLE 32G 1/4 | 79, 83, 84 |
| PENTIPS PEN NEEDLE 32GX5/32. | 79, 83, 84 |
| perphenazine-amitriptyline | 10 |
| phenobarbital..... | 129 |
| pimecrolimus..... | 130 |
| PIP PEN NEEDLE 31G X 5MM.. | 79, 83, 84 |
| PIP PEN NEEDLE 32G X 4MM.. | 79, 83, 84 |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 16, 17 |
| pirfenidone oral capsule..... | 52 |
| pirfenidone oral tablet 267 mg, 534 mg, 801 mg | 52 |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | 85 |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | 85 |
| POMALYST | 16, 17 |
| posaconazole oral..... | 131 |
| PRADAXA ORAL PELLETS IN PACKET | 132 |
| pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg | 102 |
| pregabalin oral solution..... | 102 |
| PREMARIN ORAL | 133 |
| PREMPRO..... | 134 |
| PREVENT PEN NEEDLE 31GX1/4. | 79, 83, 84 |
| PREVENT PEN NEEDLE 31GX5/16 | 79, 83, 84 |
| PREVYMIS ORAL TABLET | 135 |
| PRO COMFORT 0.5 ML 30GX1/2... .. | 79, 83, 84 |

PRO COMFORT 0.5 ML 30GX5/16. 80, 83, 84
 PRO COMFORT 0.5 ML 31GX5/16. 80, 83, 84
 PRO COMFORT 1 ML 30GX1/2. 80, 83, 84
 PRO COMFORT 1 ML 30GX5/16.... 80, 83, 84
 PRO COMFORT 1 ML 31GX5/16.... 80, 83, 84
 PRO COMFORT ALCOHOL 70% PADS 80, 83, 84
 PRO COMFORT PEN NDL 31GX5/16.. 80, 83, 84
 PRO COMFORT PEN NDL 32G X 1/4.. 80, 83, 84
 PRO COMFORT PEN NDL 4MM 32G.. 80, 83, 84
 PRO COMFORT PEN NDL 5MM 32G.. 80, 83, 84
 PROCRT..... 136
 PRODIGY INS SYR 1 ML 28GX1/2 80, 83, 84
 PRODIGY SYRNG 0.5 ML 31GX5/16 .. 80, 83, 84
 PRODIGY SYRNGE 0.3 ML 31GX5/16 80, 83, 84
 PROLASTIN-C INTRAVENOUS SOLUTION..... 137
 PROLIA 138
 PROMACTA 139
 promethazine oral..... 140
 promethazine rectal suppository 12.5 mg, 25 mg 140
 promethegan rectal suppository 25 mg, 50 mg 140
 protriptyline..... 141
 PURE CMFT SFTY PEN NDL 31G 5MM 80, 83, 84
 PURE CMFT SFTY PEN NDL 31G 6MM 80, 83, 84
 PURE CMFT SFTY PEN NDL 32G 4MM 80, 83, 84
 PURE COMFORT ALCOHOL 70% PADS 80, 83, 84
 PURE COMFORT PEN NDL 32G 4MM 80, 83, 84

PURE COMFORT PEN NDL 32G 5MM 80, 83, 84
 PURE COMFORT PEN NDL 32G 6MM 80, 83, 84
 PURE COMFORT PEN NDL 32G 8MM 80, 83, 84
 PURIXAN..... 16, 17
 pyrimethamine 142
Q
 QINLOCK..... 16, 17
 quinine sulfate..... 143
R
 RAYA SURE PEN NEEDLE 29G 12MM 80, 83, 84
 RAYA SURE PEN NEEDLE 31G 4MM 80, 83, 84
 RAYA SURE PEN NEEDLE 31G 5MM 80, 83, 84
 RAYA SURE PEN NEEDLE 31G 6MM 80, 83, 84
 REBIF (WITH ALBUMIN) 85
 REBIF REBIDOSE..... 85
 REBIF TITRATION PACK 85
 RELION INS SYR 0.3 ML 31GX6MM.. 80, 83, 84
 RELION INS SYR 0.5 ML 31GX6MM.. 80, 83, 84
 RELION INS SYR 1 ML 31GX15/6480, 83, 84
 RELI-ON INSULIN 0.5 ML SYR 80, 83, 84
 RELI-ON INSULIN 1 ML SYR... 80, 83, 84
 RELION MINI PEN 31G X 1/4 ... 80, 83, 84
 REPATHA PUSHTRONEX..... 144
 REPATHA SURECLICK..... 144
 REPATHA SYRINGE..... 144
 RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML ... 145
 RETEVMO ORAL CAPSULE 40 MG, 80 MG 16, 17
 RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG 16, 17
 REVLIMID 16, 17
 REVUFORJ ORAL TABLET 110 MG, 160 MG 16, 17

REXULTI ORAL TABLET 146
 REZLIDHIA 16, 17
 REZUROCK..... 147
 RINVOQ LQ..... 148, 149
 RINVOQ ORAL TABLET EXTENDED
 RELEASE 24 HR 15 MG, 30 MG, 45
 MG 148, 149
 RISPERDAL CONSTA..... 150
 risperidone microspheres 150
 roflumilast..... 36
 ROZLYTREK ORAL CAPSULE 100 MG,
 200 MG 16, 17
 ROZLYTREK ORAL PELLETS IN
 PACKET..... 16, 17
 RUBRACA 16, 17
 rufinamide oral suspension 151
 rufinamide oral tablet..... 151
 RYBELSUS ORAL TABLET 14 MG, 3
 MG, 7 MG..... 63
 RYDAPT..... 16, 17
S
 SAFESNAP INS SYR UNITS-100 0.3 ML
 30GX5/16..... 80, 83, 84
 SAFESNAP INS SYR UNITS-100 0.5 ML
 29GX1/2..... 80, 83, 84
 SAFESNAP INS SYR UNITS-100 0.5 ML
 30GX5/16..... 80, 83, 84
 SAFESNAP INS SYR UNITS-100 1 ML
 28GX1/2..... 80, 83, 84
 SAFESNAP INS SYR UNITS-100 1 ML
 29GX1/2..... 80, 83, 84
 SAFETY PEN NEEDLE 31G 4MM . 80, 83,
 84
 SAFETY PEN NEEDLE 5MM X 31G ... 80,
 83, 84
 SAFETY SYRINGE 0.5 ML 30G 1/2 80, 83,
 84
 sapropterin..... 152
 SCEMBLIX ORAL TABLET 100 MG, 20
 MG, 40 MG..... 16, 17
 SECUADO..... 153
 SECURESAFE PEN NDL 30GX5/1680, 83,
 84
 SECURESAFE SYR 0.5 ML 29G 1/280, 83,
 84
 SECURESAFE SYRNG 1 ML 29G 1/2.. 80,
 83, 84
 SIGNIFOR 154
 sildenafil (pulm.hypertension) oral tablet 127
 SIRTURO ORAL TABLET 100 MG..... 155
 SKY SAFETY PEN NEEDLE 30G 5MM
 80, 83, 84
 SKY SAFETY PEN NEEDLE 30G 8MM
 80, 83, 84
 SKYRIZI SUBCUTANEOUS PEN
 INJECTOR..... 156
 SKYRIZI SUBCUTANEOUS SYRINGE
 150 MG/ML..... 156
 SKYRIZI SUBCUTANEOUS WEARABLE
 INJECTOR..... 156
 SM ULT CFT 0.3 ML 31GX5/16(1/2).... 80,
 83, 84
 sodium oxybate 200
 sofosbuvir-velpatasvir..... 157
 SOMAVERT..... 158
 sorafenib..... 16, 17
 SPRITAM 159
 SPRYCEL ORAL TABLET 100 MG, 140
 MG, 20 MG, 50 MG, 70 MG, 80 MG . 16,
 17
 STELARA SUBCUTANEOUS..... 160
 STERILE PADS 2 80, 83, 84
 STIVARGA 16, 17
 sunitinib malate..... 16, 17
 SURE CMFT SFTY PEN NDL 31G 6MM
 80, 83, 84
 SURE CMFT SFTY PEN NDL 32G 4MM
 80, 83, 84
 SURE COMFORT 0.5 ML SYRINGE.... 80,
 83, 84
 SURE COMFORT 1 ML SYRINGE. 80, 83,
 84
 SURE COMFORT 3/10 ML SYRINGE.. 80,
 83, 84
 SURE COMFORT 3/10 ML SYRINGE
 INSULIN SYRINGE 80, 83, 84
 SURE COMFORT 30G PEN NEEDLE.. 80,
 83, 84
 SURE COMFORT ALCOHOL PREP
 PADS 80, 83, 84

| | |
|---|--|
| SURE COMFORT INS 0.3 ML 31GX1/480, 83, 84 | TAKHZYRO..... 165 |
| SURE COMFORT INS 0.5 ML 31GX1/480, 83, 84 | TALTZ AUTOINJECTOR..... 166 |
| SURE COMFORT INS 1 ML 31GX1/4.. 80, 83, 84 | TALTZ SYRINGE..... 166 |
| SURE COMFORT PEN NDL 29GX1/2 . 80, 83, 84 | TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG 16, 17 |
| SURE COMFORT PEN NDL 31G 5MM 80, 83, 84 | TARGRETIN TOPICAL 167 |
| SURE COMFORT PEN NDL 31G 8MM 80, 83, 84 | TASIGNA 16, 17 |
| SURE COMFORT PEN NDL 32G 4MM 80, 83, 84 | TAVNEOS 168 |
| SURE COMFORT PEN NDL 32G 6MM 80, 83, 84 | tazarotene topical cream 169 |
| SURE-FINE PEN NEEDLES 12.7MM... 80, 83, 84 | tazarotene topical gel 169 |
| SURE-FINE PEN NEEDLES 5MM.. 80, 83, 84 | TAZORAC TOPICAL CREAM 0.05 % 169 |
| SURE-FINE PEN NEEDLES 8MM.. 80, 83, 84 | TAZORAC TOPICAL GEL 169 |
| SURE-JECT INSU SYR U100 0.3 ML... 80, 83, 84 | TAZVERIK..... 16, 17 |
| SURE-JECT INSU SYR U100 0.5 ML... 80, 83, 84 | TECHLITE 0.3 ML 29GX12MM (1/2)... 80, 83, 84 |
| SURE-JECT INSU SYR U100 1 ML 80, 83, 84 | TECHLITE 0.3 ML 30GX12MM (1/2)... 80, 83, 84 |
| SURE-JECT INSUL SYR U100 1 ML ... 80, 83, 84 | TECHLITE 0.3 ML 30GX8MM (1/2)80, 83, 84 |
| SURE-JECT INSULIN SYRINGE 1 ML 80, 83, 84 | TECHLITE 0.3 ML 31GX6MM (1/2)80, 83, 84 |
| SURE-PREP ALCOHOL PREP PADS .. 80, 83, 84 | TECHLITE 0.3 ML 31GX8MM (1/2)80, 83, 84 |
| SUTENT 16, 17 | TECHLITE 0.5 ML 30GX12MM (1/2)... 80, 83, 84 |
| SYMPAZAN..... 161 | TECHLITE 0.5 ML 30GX8MM (1/2)80, 83, 84 |
| SYNAREL 162 | TECHLITE 0.5 ML 31GX6MM (1/2)80, 83, 84 |
| T | TECHLITE 0.5 ML 31GX8MM (1/2)81, 83, 84 |
| TABLOID 16, 17 | TECHLITE INS SYR 1 ML 29GX12MM 81, 83, 84 |
| TABRECTA 16, 17 | TECHLITE INS SYR 1 ML 30GX12MM 81, 83, 84 |
| tacrolimus topical..... 163 | TECHLITE INS SYR 1 ML 30GX8MM 81, 83, 84 |
| tadalafil (pulm. hypertension)..... 127 | TECHLITE INS SYR 1 ML 31GX6MM 81, 83, 84 |
| tadalafil oral tablet 5 mg 164 | TECHLITE INS SYR 1 ML 31GX8MM 81, 83, 84 |
| TADLIQ..... 127 | TECHLITE PEN NEEDLE 29GX1/2 81, 83, 84 |
| TAFINLAR..... 16, 17 | TECHLITE PEN NEEDLE 29GX3/8 81, 83, 84 |
| TAGRISSO 16, 17 | |

| | | | |
|--|------------|--------------------------------|------------|
| TECHLITE PEN NEEDLE 31GX1/4 | 81, 83, 84 | tobramycin in 0.225 % nacl | 176 |
| TECHLITE PEN NEEDLE 31GX3/16 | 81, 83, 84 | tobramycin inhalation | 176 |
| TECHLITE PEN NEEDLE 31GX5/16 | 81, 83, 84 | tolcapone | 177 |
| TECHLITE PEN NEEDLE 32GX1/4 | 81, 83, 84 | TOPCARE CLICKFINE 31G X 1/4. | 81, 83, 84 |
| TECHLITE PEN NEEDLE 32GX5/16 | 81, 83, 84 | TOPCARE CLICKFINE 31G X 5/16 | 81, 83, 84 |
| TECHLITE PEN NEEDLE 32GX5/32 | 81, 83, 84 | TOPCARE ULTRA COMFORT SYRINGE | 81, 83, 84 |
| TECHLITE PLUS PEN NDL 32G 4MM | 81, 83, 84 | torpenz | 16, 17 |
| TEPMETKO | 16, 17 | TRELSTAR INTRAMUSCULAR | |
| teriflunomide | 24 | SUSPENSION FOR | |
| teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml) | 126 | RECONSTITUTION | 178 |
| TERUMO INS SYRINGE U100-1 ML | 81, 83, 84 | trientine oral capsule 250 mg | 179 |
| TERUMO INS SYRINGE U100-1/2 ML | 81, 83, 84 | trihexyphenidyl | 180 |
| TERUMO INS SYRINGE U100-1/3 ML | 81, 83, 84 | trimipramine | 181 |
| TERUMO INS SYRNG U100-1/2 ML | 81, 83, 84 | TRINTELLIX | 182 |
| testosterone cypionate | 171 | TRUE CMFRT PRO 0.5 ML 30G 5/16 | 81, 83, 84 |
| testosterone enanthate | 171 | TRUE CMFRT PRO 0.5 ML 31G 5/16 | 81, 83, 84 |
| testosterone transdermal gel in metered-dose pump | 171, 172 | TRUE CMFRT PRO 0.5 ML 32G 5/16 | 81, 83, 84 |
| testosterone transdermal gel in packet | 171, 172 | TRUE CMFT SFTY PEN NDL 31G 5MM | 81, 83, 84 |
| testosterone transdermal solution in metered pump w/app | 171 | TRUE CMFT SFTY PEN NDL 31G 6MM | 81, 83, 84 |
| tetrabenazine | 173 | TRUE CMFT SFTY PEN NDL 32G 4MM | 81, 83, 84 |
| THALOMID | 16, 17 | TRUE COMFORT 0.5 ML 30G 1/2 | 81, 83, 84 |
| THINPRO INS SYRIN U100-0.3 ML | 81, 83, 84 | TRUE COMFORT 0.5 ML 30G 5/16 | 81, 83, 84 |
| THINPRO INS SYRIN U100-0.5 ML | 81, 83, 84 | TRUE COMFORT 0.5 ML 31G 5/16 | 81, 83, 84 |
| THINPRO INS SYRIN U100-1 ML | 81, 83, 84 | TRUE COMFORT 0.5 ML 31GX5/16 | 81, 83, 84 |
| thioridazine | 66 | TRUE COMFORT 1 ML 31GX5/16 | 81, 83, 84 |
| TIBSOVO | 16, 17 | TRUE COMFORT ALCOHOL 70% PADS | 81, 83, 84 |
| tigecycline | 174 | TRUE COMFORT PEN NDL 31G 8MM | 81, 83, 84 |
| TOBI PODHALER | 175 | TRUE COMFORT PEN NDL 31GX5MM | 81, 83, 84 |

TRUE COMFORT PEN NDL 31GX6MM 81, 83, 84
TRUE COMFORT PEN NDL 32G 5MM81, 83, 84
TRUE COMFORT PEN NDL 32G 6MM81, 83, 84
TRUE COMFORT PEN NDL 32GX4MM 81, 83, 84
TRUE COMFORT PEN NDL 33G 4MM81, 83, 84
TRUE COMFORT PEN NDL 33G 5MM81, 83, 84
TRUE COMFORT PEN NDL 33G 6MM81, 83, 84
TRUE COMFORT PRO 1 ML 30G 1/2.. 81, 83, 84
TRUE COMFORT PRO 1 ML 30G 5/16 81, 83, 84
TRUE COMFORT PRO 1 ML 31G 5/16 81, 83, 84
TRUE COMFORT PRO 1 ML 32G 5/16 81, 83, 84
TRUE COMFORT PRO ALCOHOL PADS 81, 83, 84
TRUE COMFORT SFTY 1 ML 30G 1/2 81, 83, 84
TRUE COMFRT PRO 0.5 ML 30G 1/2.. 81, 83, 84
TRUE COMFRT SFTY 1 ML 30G 5/16. 81, 83, 84
TRUE COMFRT SFTY 1 ML 31G 5/16. 81, 83, 84
TRUE COMFRT SFTY 1 ML 32G 5/16. 81, 83, 84
TRUEPLUS PEN NEEDLE 29GX1/2 81, 83, 84
TRUEPLUS PEN NEEDLE 31G X 1/4 .. 81, 83, 84
TRUEPLUS PEN NEEDLE 31GX3/16 .. 81, 83, 84
TRUEPLUS PEN NEEDLE 31GX5/16 .. 81, 83, 84
TRUEPLUS PEN NEEDLE 32GX5/32 .. 81, 83, 84
TRUEPLUS SYR 0.3 ML 29GX1/2.. 81, 83, 84
TRUEPLUS SYR 0.3 ML 30GX5/16 81, 83, 84
TRUEPLUS SYR 0.3 ML 31GX5/16 81, 83, 84
TRUEPLUS SYR 0.5 ML 28GX1/2.. 81, 83, 84
TRUEPLUS SYR 0.5 ML 29GX1/2.. 81, 83, 84
TRUEPLUS SYR 0.5 ML 30GX5/16 81, 83, 84
TRUEPLUS SYR 0.5 ML 31GX5/16 81, 83, 84
TRUEPLUS SYR 1 ML 28GX1/2 81, 83, 84
TRUEPLUS SYR 1 ML 29GX1/2 81, 83, 84
TRUEPLUS SYR 1 ML 30GX5/16... 81, 83, 84
TRUEPLUS SYR 1 ML 31GX5/16... 81, 83, 84
TRULICITY 63
TRUQAP..... 16, 17
TUKYSA ORAL TABLET 150 MG, 50 MG 16, 17
TURALIO ORAL CAPSULE 125 MG, 200 MG 16, 17
TYMLOS 126
U
UBRELVY..... 183
UDENYCA..... 128
UDENYCA AUTOINJECTOR..... 128
UDENYCA ONBODY 128
ULTICAR INS 0.3 ML 31GX1/4(1/2) 81, 83, 84
ULTICARE INS 1 ML 31GX1/4 . 81, 83, 84
ULTICARE INS SYR 0.3 ML 30G 8MM 81, 83, 84
ULTICARE INS SYR 0.3 ML 31G 6MM 81, 83, 84
ULTICARE INS SYR 0.3 ML 31G 8MM 81, 83, 84
ULTICARE INS SYR 0.5 ML 31G 6MM 81, 83, 84
ULTICARE INS SYR 1 ML 30GX1/2.... 81, 83, 84
ULTICARE PEN NEEDLE 31GX3/16... 81, 83, 84

ULTICARE PEN NEEDLE 6MM 31G... 81,
 83, 84
 ULTICARE PEN NEEDLE 8MM 31G... 81,
 83, 84
 ULTICARE PEN NEEDLES 12MM 29G
 81, 83, 84
 ULTICARE PEN NEEDLES 4MM 32G
 MICRO, 32GX4MM..... 81, 83, 84
 ULTICARE PEN NEEDLES 6MM 32G 81,
 83, 84
 ULTICARE SAFE PEN NDL 30G 8MM 82,
 83, 84
 ULTICARE SAFE PEN NDL 5MM 30G 82,
 83, 84
 ULTICARE SYR 0.3 ML 29G 12.7MM. 82,
 83, 84
 ULTICARE SYR 0.3 ML 30GX1/2.. 82, 83,
 84
 ULTICARE SYR 0.3 ML 31GX5/16 82, 83,
 84
 ULTICARE SYR 0.5 ML 30GX1/2.. 82, 83,
 84
 ULTICARE SYR 0.5 ML 31GX5/16 82, 83,
 84
 ULTICARE SYR 1 ML 31GX5/16... 82, 83,
 84
 ULTIGUARD SAFE 1 ML 30G 12.7MM
 82, 83, 84
 ULTIGUARD SAFE0.3 ML 30G 12.7MM
 82, 83, 84
 ULTIGUARD SAFE0.5 ML 30G 12.7MM
 82, 83, 84
 ULTIGUARD SAFEPACK 1 ML 31G
 8MM 82, 83, 84
 ULTIGUARD SAFEPACK 29G 12.7MM
 82, 83, 84
 ULTIGUARD SAFEPACK 31G 5MM... 82,
 83, 84
 ULTIGUARD SAFEPACK 31G 6MM... 82,
 83, 84
 ULTIGUARD SAFEPACK 31G 8MM... 82,
 83, 84
 ULTIGUARD SAFEPACK 32G 4MM... 82,
 83, 84
 ULTIGUARD SAFEPACK 32G 6MM... 82,
 83, 84

ULTIGUARD SAFEPK 0.3 ML 31G 8MM
 82, 83, 84
 ULTIGUARD SAFEPK 0.5 ML 31G 8MM
 82, 83, 84
 ULTILET ALCOHOL STERL SWAB ... 82,
 83, 84
 ULTILET INSULIN SYRINGE 0.3 ML. 82,
 83, 84
 ULTILET INSULIN SYRINGE 0.5 ML. 82,
 83, 84
 ULTILET INSULIN SYRINGE 1 ML.... 82,
 83, 84
 ULTILET PEN NEEDLE 82, 83, 84
 ULTILET PEN NEEDLE 4MM 32G 82, 83,
 84
 ULTRA COMFORT 0.3 ML SYRINGE. 82,
 83, 84
 ULTRA COMFORT 0.5 ML 28GX1/2 ... 82,
 83, 84
 ULTRA COMFORT 0.5 ML 29GX1/2 ... 82,
 83, 84
 ULTRA COMFORT 0.5 ML SYRINGE. 82,
 83, 84
 ULTRA COMFORT 1 ML 31GX5/16.... 82,
 83, 84
 ULTRA COMFORT 1 ML SYRINGE.... 82,
 83, 84
 ULTRA FLO 0.3 ML 30G 1/2..... 82, 83, 84
 ULTRA FLO 0.3 ML 30G 5/16.... 82, 83, 84
 ULTRA FLO 0.3 ML 31G 5/16.... 82, 83, 84
 ULTRA FLO PEN NEEDLE 31G 5MM. 82,
 83, 84
 ULTRA FLO PEN NEEDLE 31G 8MM. 82,
 83, 84
 ULTRA FLO PEN NEEDLE 32G 4MM. 82,
 83, 84
 ULTRA FLO PEN NEEDLE 33G 4MM. 82,
 83, 84
 ULTRA FLO PEN NEEDLES 12MM 29G
 82, 83, 84
 ULTRA FLO SYR 0.3 ML 29GX1/2 82, 83,
 84
 ULTRA FLO SYR 0.3 ML 30G 5/16 82, 83,
 84
 ULTRA FLO SYR 0.3 ML 31G 5/16 82, 83,
 84

ULTRA FLO SYR 0.5 ML 29G 1/2.. 82, 83,
 84
 ULTRA THIN PEN NDL 32G X 4MM.. 82,
 83, 84
 ULTRACARE INS 0.3 ML 30GX5/16 ... 82,
 83, 84
 ULTRACARE INS 0.3 ML 31GX5/16 ... 82,
 83, 84
 ULTRACARE INS 0.5 ML 30GX1/2 82, 83,
 84
 ULTRACARE INS 0.5 ML 30GX5/16 ... 82,
 83, 84
 ULTRACARE INS 0.5 ML 31GX5/16 ... 82,
 83, 84
 ULTRACARE INS 1 ML 30G X 5/16 82,
 83, 84
 ULTRACARE INS 1 ML 30GX1/2 .. 82, 83,
 84
 ULTRACARE INS 1 ML 31G X 5/16 82,
 83, 84
 ULTRACARE PEN NEEDLE 31GX1/4. 82,
 83, 84
 ULTRACARE PEN NEEDLE 31GX3/1682,
 83, 84
 ULTRACARE PEN NEEDLE 31GX5/1682,
 83, 84
 ULTRACARE PEN NEEDLE 32GX1/4. 82,
 83, 84
 ULTRACARE PEN NEEDLE 32GX3/1682,
 83, 84
 ULTRACARE PEN NEEDLE 32GX5/3282,
 83, 84
 ULTRACARE PEN NEEDLE 33GX5/3282,
 83, 84
 ULTRA-FINE 0.3 ML 31G 6MM (1/2) .. 82,
 83, 84
 ULTRA-FINE 0.3 ML 31G 8MM (1/2) .. 82,
 83, 84
 ULTRA-FINE PEN NDL 29G 12.7MM . 82,
 83, 84
 ULTRA-FINE PEN NEEDLE 32G 6MM82,
 83, 84
 ULTRA-THIN II 1 ML 31GX5/1682, 83, 84
 ULTRA-THIN II INS 0.3 ML 30G ... 82, 83,
 84

ULTRA-THIN II INS 0.3 ML 31G ... 82, 83,
 84
 ULTRA-THIN II INS 0.5 ML 29G ... 82, 83,
 84
 ULTRA-THIN II INS 0.5 ML 30G ... 82, 83,
 84
 ULTRA-THIN II INS 0.5 ML 31G ... 82, 83,
 84
 ULTRA-THIN II INS SYR 1 ML 29G.... 82,
 83, 84
 ULTRA-THIN II INS SYR 1 ML 30G.... 82,
 83, 84
 ULTRA-THIN II PEN NDL 29GX1/2 82,
 83, 84
 ULTRA-THIN II PEN NDL 31GX5/16.. 82,
 83, 84
 UNIFINE PEN NEEDLE 32G 4MM 82, 83,
 84
 UNIFINE PENTIPS 12MM 29G
 29GX12MM, STRL..... 82, 83, 84
 UNIFINE PENTIPS 31GX3/16.... 82, 83, 84
 UNIFINE PENTIPS 32GX1/4..... 82, 83, 84
 UNIFINE PENTIPS 32GX5/32.... 82, 83, 84
 UNIFINE PENTIPS 33GX5/32.... 82, 83, 84
 UNIFINE PENTIPS 6MM 31G..... 83, 84
 UNIFINE PENTIPS MAX 30GX3/16 83, 84
 UNIFINE PENTIPS NEEDLES 29G. 83, 84
 UNIFINE PENTIPS PLUS 29GX1/2. 83, 84
 UNIFINE PENTIPS PLUS 30GX3/1683, 84
 UNIFINE PENTIPS PLUS 31GX1/4. 83, 84
 UNIFINE PENTIPS PLUS 31GX3/1683, 84
 UNIFINE PENTIPS PLUS 31GX5/1683, 84
 UNIFINE PENTIPS PLUS 32GX5/32 83, 84
 UNIFINE PENTIPS PLUS 33GX5/32 83, 84
 UNIFINE PROTECT 30G 5MM..... 83, 84
 UNIFINE PROTECT 30G 8MM..... 83, 84
 UNIFINE PROTECT 32G 4MM..... 83, 84
 UNIFINE SAFECONTROL 30G 5MM.. 83,
 84
 UNIFINE SAFECONTROL 30G 8MM.. 83,
 84
 UNIFINE SAFECONTROL 31G 5MM.. 83,
 84
 UNIFINE SAFECONTROL 31G 6MM.. 83,
 84

UNIFINE SAFECONTROL 31G 8MM.. 83,
 84
 UNIFINE SAFECONTROL 32G 4MM.. 83,
 84
 UNIFINE ULTRA PEN NDL 31G 5MM 83,
 84
 UNIFINE ULTRA PEN NDL 31G 6MM 83,
 84
 UNIFINE ULTRA PEN NDL 31G 8MM 83,
 84
 UNIFINE ULTRA PEN NDL 32G 4MM 83,
 84
 UZEDY 150
V
 VALCHLOR..... 184
 vancomycin oral capsule 125 mg, 250 mg
 185
 VANFLYTA..... 16, 17
 VANISHPOINT 0.5 ML 30GX1/2..... 83, 84
 VANISHPOINT INS 1 ML 30GX3/16 ... 83,
 84
 VANISHPOINT U-100 29X1/2 SYR. 83, 84
 VEMLIDY 186
 VENCLEXTA..... 16, 17
 VENCLEXTA STARTING PACK 16, 17
 VEOZAH 187
 VERIFINE INS SYR 1 ML 29G 1/2 .. 83, 84
 VERIFINE PEN NEEDLE 29G 12MM .. 83,
 84
 VERIFINE PEN NEEDLE 31G 5MM 83, 84
 VERIFINE PEN NEEDLE 31G X 6MM 83,
 84
 VERIFINE PEN NEEDLE 31G X 8MM 83,
 84
 VERIFINE PEN NEEDLE 32G 6MM 83, 84
 VERIFINE PEN NEEDLE 32G X 4MM 83,
 84
 VERIFINE PEN NEEDLE 32G X 5MM 83,
 84
 VERIFINE PLUS PEN NDL 31G 5MM. 83,
 84
 VERIFINE PLUS PEN NDL 31G 8MM. 83,
 84
 VERIFINE PLUS PEN NDL 32G 4MM. 83,
 84

VERIFINE PLUS PEN NDL 32G 4MM-
 SHARPS CONTAINER 83, 84
 VERIFINE SYRING 0.5 ML 29G 1/2 83, 84
 VERIFINE SYRING 1 ML 31G 5/16 83, 84
 VERIFINE SYRNG 0.3 ML 31G 5/16 83, 84
 VERIFINE SYRNG 0.5 ML 31G 5/16 83, 84
 VERQUVO 188
 VERSALON ALL PURPOSE SPONGE
 25'S,N-STERILE,3PLY 83, 84
 VERZENIO..... 16, 17
 VIBERZI..... 189
 VIIBRYD ORAL TABLET..... 190
 vilazodone 190
 VITRAKVI ORAL CAPSULE 100 MG, 25
 MG 16, 17
 VITRAKVI ORAL SOLUTION 16, 17
 VIZIMPRO 16, 17
 VONJO 16, 17
 VORANIGO ORAL TABLET 10 MG, 40
 MG 16, 17
 voriconazole intravenous 191
 VOTRIENT..... 16, 17
 VOWST 192
 VRAYLAR ORAL CAPSULE..... 119
 VRAYLAR ORAL CAPSULE,DOSE
 PACK..... 119
W
 WEBCOL ALCOHOL PREPS
 20'S,LARGE 83, 84
 WEGOVY..... 193
 WELIREG..... 16, 17
X
 XALKORI ORAL CAPSULE..... 16, 17
 XALKORI ORAL PELLETT 150 MG, 20
 MG, 50 MG..... 17
 XATMEP 194
 XDEMVY 195
 XELJANZ ORAL SOLUTION 196
 XELJANZ ORAL TABLET..... 196
 XELJANZ XR 196
 XERMELO 17
 XGEVA..... 197
 XIFAXAN..... 198
 XOLAIR 199
 XOSPATA 17

| | |
|---|-----|
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK) | 17 |
| XTANDI | 17 |
| XYREM | 200 |
| Y | |
| YONSA..... | 17 |
| Z | |
| ZARXIO | 201 |

| | |
|--|-----|
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG..... | 17 |
| ZELBORAF | 17 |
| ZEPATIER..... | 202 |
| ZIEXTENZO | 128 |
| ziprasidone mesylate..... | 59 |
| ZOLINZA | 17 |
| ZYDELIG | 17 |
| ZYKADIA | 17 |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG... | 203 |